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GENETIC AND CLINICAL DETERMINANTS OF RACIAL/ETHNIC DIFFERENCES IN 
MULTIPLE MYELOMA SUSCEPTIBILITY AND OUTCOMES FOCUSING ON HISPANICS  
 
Alem Abebe Belachew, M.S. 
Advisory Professor: Michelle A. T. Hildebrandt, Ph.D. 
 
Multiple Myeloma (MM)  constitutes 10% of diagnosed hematologic malignancies in 
the US, with over 12,000 deaths recorded each year. Race/ethnicity is a well-known MM 
risk factor, where individuals of African descent have over 2- to 3-fold increased risk of 
incidence compared to those of European descent. Additionally, Hispanics are diagnosed 
approximately three years younger than white American counterparts, for unknown 
reasons. Differences in clinical phenotype are also present for MM patients by ancestry, 
including varying rates of common initiation mutations such as IgH translocations and TP53 
mutation between patients of European and African descent. Studies have begun to 
interrogate the genetic basis for differences in MM susceptibility and other clinical 
endpoints in populations of European and African lineage. However, there is a gap in our 
understanding of the genetic etiology of MM susceptibility in Hispanics. Furthermore, MM 
clinical features have yet to be described in Hispanics, precluding genetic studies of MM 
clinical outcomes by race/ethnicity.  
This study examined the effect of genetic ancestral background on MM 
susceptibility and clinical endpoints by utilizing the genome-wide genotype dataset and 
robust medical records of a multi-ethnic patient population seen at MD Anderson Cancer 
Center. We conducted case-control association analysis in 143 self-identified Hispanic, 211 
non-Hispanic black, 262 non-Hispanic white MM cases, and 633 healthy controls. We also 
 vi 
described MM clinical characteristics at diagnosis in Hispanic patients and performed a 
comparative analysis of clinical phenotypes by self-reported ethnicity and genetic ancestry.  
We discovered differential risk in MM susceptibility by genetic ancestry. We also 
identified unique patterns in Hispanics' baseline clinical phenotype compared to self-
reported non-Hispanic black and non-Hispanic white patients. Our study also revealed 
Hispanics with elevated European ancestry to be at an increased risk of genetic 
abnormalities associated with poor MM prognosis. Moreover, we identified genetic variants 
within the Wnt/beta-catenin pathway associated with MM risk that vary by race/ethnicity.  
Our findings may be clinically applicable to filling the knowledge gap regarding the 
genetic contributors of MM susceptibility and outcomes in diverse patient populations and 
towards eliminating self-report bias of race/ethnicity to better define risk associations and 
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Multiple Myeloma (MM) Epidemiology and Disease Overview 
 
Multiple Myeloma (MM) makes up ~10% of diagnosed hematologic malignancies 
in the U.S., with over 32,000 new cases and over 12,000 deaths recorded each 
year(1). The median age of diagnosis is 69, with the elderly (age > 75) making up most 
cases(2). Although MM accounts for only 1.8% of all cancers, it is an incurable disease 
with a high symptom burden due to the physical manifestation of the disease, such as 
bone destruction, which impairs patients’ quality of life(3). Improved management 
strategies and novel effective treatments have dramatically improved MM outcomes 
over the past two decades(4). Nevertheless, almost all MM patients frequently relapse, 
and remain on chemotherapy for the rest of their lives(5).  
As a blood disorder, MM is characterized by the overproduction of clonal plasma 
cells and elevated levels of monoclonal immunoglobulin (M-proteins) in the bone 
marrow. Furthermore, end organ damage events described by hypercalcemia, renal 
insufficiency, anemia, and lytic bone lesions, collectively known as the CRAB criteria, 
signify active MM requiring treatment.  
The etiology of MM is not fully known. However, a small number of risk factors 
have been associated with an increased incidence of MM, including older age and high 
body mass index reported by a meta-analysis showing a risk ratio of 1.12 for 
overweight individuals, and a 1.21 risk ratio for those that were obese(6). In contrast, 
some studies reported an inverse relationship between MM incidence and 
fruit/vegetable consumptions(7, 8). Also, MM is more common in men and individuals 
of African descent(9), which will be further elaborated in the next section. Interestingly, 
MM displays geographical differences in incidence that as of yet have unclear reasons. 
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North American and European countries report the highest incidence rates, followed by 
populations of Southern and Middle African origins, as well as Caribbean countries. 
Asian countries and U.S residents of Asian descent report the lowest incidences(10). 
Other MM risk factors include environmental and occupational hazard through 
exposure to chemical agents, including pesticides, organic solvents, and hair dyes(11). 
A group from Sloan Kettering published a strong supporting study for the role of 
occupational exposures on MM susceptibility, which showed a disproportionate number 
of firefighters exposed to the 9/11 World Trade Center disaster in 2001 who were at an 
increased risk of early-onset aggressive MM(12).  
Genetics also play a role in MM susceptibility. Individuals with a family history of 
MM and other hematological malignancies, including 1st degree relatives, were also 
shown to have a substantial increase of MM incidence(10). Germline genetic studies 
have identified 23 MM susceptibility loci in individuals of European descent(13). Almost 
all identified risk loci, including 8q24.21, 6p22.3, 3p22.1, and 7p15.3(14–17), are 
located in non-coding regions suggesting their influence via gene regulation. 
Furthermore, two recent meta-analyses comparing patients of African and European 
ancestry found overlap between 20 of the 23 prior reported risk regions, suggesting 
shared susceptibility loci across populations(18), with MM risk association variation on 
p23.3, 17p11.2, 3p22.1, 22q13.1, 7p15.3 regions between African and European 
ancestry(19). One epigenetic study identified hyperphosphorylation of the antigenic 
paraprotein target protein, paratarg-7 (pP-7), which is overexpressed in MM, to occur in 
a substantially higher frequency in patients of African descent, suggesting differential 
epigenetic events by ancestral lineage leading to MM incidence via antigenic 
stimulation(20). Nevertheless, much of MM's genetic etiology and hereditability remain 
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unknown, and MM progression cannot be linked to any unique genetic or 
environmental event.  
Moreover, MM is preceded by asymptomatic conditions, namely monoclonal 
gammopathy of undermined significance (MGUS) and smoldering myeloma (SMM)(21). 
MGUS is characterized by < 10 % clonal plasma cells infiltration in the bone marrow 
with < 3g/dL of M-protein(22) where SMM presents > 3 g/dL serum M-protein and/or 
10-60% of plasma cells in the bone marrow(23), but without manifestation of CRAB 
features. Due to a lack of population-based registries or systematic screening programs 
for MGUS and SMM, the prevalence rate of these conditions is difficult to estimate. 
However, approximately 3.2% of Caucasians over 50 are estimated to be living with 
MGUS based on data from a retrospective study on 28,000+ individuals who 
underwent routine clinical screening at the Mayo Clinic(24). Interestingly a nation-wide 
study of over 4 million individuals admitted to 142 Veterans Affairs hospitals found an 
MGUS prevalence rate 2 to 3-fold higher in African Americans compared to whites(22), 
for reasons that remain unclear. This striking disparity in MGUS prevalence by 
race/ethnicity is also a recurring trend in MM susceptibility and will be discussed further 
in the next section.  
The estimated SMM incidence rate is 0.9 cases per 100,000 persons(25) with 
varying risk of MM progression based on the burden of circulating plasma cell, serum 
light chain ratio produced by the monoclonal antibodies, mutational events, and 
suggestions of approaching end-organ damage(26). SMM patients with bone marrow 
plasma cell > 60%, free light chain ratio of > 100, and more than one focal lesions 
detected by radiographic imaging are classified as having high-risk SMM and are often 
treated(27). While not all MGUS and SMM patients will develop MM, the likelihood to 
progression increases by 1% and 10% per year, respectively(27).  
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The spectrum of plasma cell expansion between MGUS, SMM, and MM has 
provided a unique platform for investigating the genomic hierarchy and clonal evolution 
of these disease stages. MM initiating primary cytogenetic subtypes can be broadly 
divided into two groups: translocations involving the immunoglobulin heavy chain (IgH) 
locus, and hyperdiploidy that are often trisomies of odd-numbered chromosomes(28). 
The most common IgH translocations include t(11;14), t(6;14), t(4;14), t(14;16) and 
t(14;20); the latter three are associated with poor prognosis(29, 30). In contrast, 
trisomic tumors are associated with favorable overall survival(31). IgH translocations 
promote overexpression and dysregulation of oncogenes cyclin D1 (CCND1), cyclin D3 
(CCND3), fibroblast growth factor receptor 3 (FGFR3), MM SET domain (MMSET), and 
transcription factors Maf and MafB(32)— leading to the accumulation of mutations 
resulting in disease progression. Secondary cytogenetic abnormalities like monosomy 
13/del13q have been identified from the onset of the disease, whereas del17p coding 
TP53, 1q gain, and the Ig translocation involving the 8q24 MYC oncogene(33, 34) are 
seen with disease progression. MGUS, SMM, and MM indeed share some of these 
genetic events. For instance, del(17p), t(4:14),1q gains, t(4;14), t(6;14), t(11;14), 
t(14;16) and t(14;20), have been found to correlate with increased risk of disease 
progression from MGUS to SMM. Cyclin D1, FGFR3, and MYC overexpression have 
also been detected in MGUS and SMM patients(35). Despite these overlaps, differing 
initiating events promote heterogenous MM with varying molecular subtypes.  
MM prognosis and staging described by the revised international staging system 
in the International Myeloma Working Group is primarily determined by biological 
markers such as tumor burden (% of plasma cells in the bone marrow), high-risk 
cytogenetic abnormalities(t(4;14), t(14;16), t(14;20), del(17/17p), elevated serum 
lactate dehydrogenase, albumin, and beta-2-microglobulin(30). Over time, patients' 
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outcomes have dramatically improved due to the introduction of autologous stem cell 
transplant (ASCT) and new treatments such as proteasome inhibitors, 
immunomodulators, and monoclonal antibodies. With advances in cancer 
management, the median survival time of patients over the last 20 years has increased 
from 4 to 8 years (36).  
The following sections will discuss the differences in MM susceptibility and 
clinical endpoints that differ by race/ethnicity and the gaps in our current knowledge of 


















Racial/Ethnic Disparities in MM 
 
Race/ethnicity is a well-known risk factor for MM. According to Surveillance 
Epidemiology and End Results (SEER) registries, blacks have over 2 to 3-fold 
increased risk MM when compared to whites and Hispanics. This disparity is thought to 
be partly due to a higher MGUS prevalence in black Americans compared to white and 
Mexican Americans(37). This excessive prevalence also continues to increase with 
progressing age in black cases. Similarly, a study comparing 917 Ghanaians to the 
predominantly white residents of Olmsted County in Minnesota, revealed a 2-fold 
increased prevalence of MGUS in the Ghanaian study group(38).  
The study was conducted to determine if shared environmental and 
socioeconomic factors in black Americans contributed to the excessive MGUS 
prevalence. However, the common genetic ancestry between Ghanaians and black 
Americans, but differing environmental conditions, support the hypothesis that genetics 
contribute to the race-related disparity in MM susceptibility in individuals with African 
ancestry. In contrast, a population-based MM incidence study of Afro-Caribbeans from 
Curaçaoa in 1993 showed an incidence rate of 3.1 to 100,000 persons(39), 
considerably lower than the US black incidence rate of 9.5 to 100,000 persons in the 
same year(40).  
Although, race/ethnicity is well known risk factor, environmental and nutritional 
factors cannot be ruled out. A retrospective study on Afro-Caribbean patients from New 
York presented a substantial higher incidence rate in females with high BMI than 
males. It is also worth noting that the rate of MM progression between in those of 
European and African descendants is constant(41), displaying that the higher 
prevalence of MGUS does not translate to faster MM progression.  
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There are notable differences in the patterns of driver genetic abnormalities by 
race/ethnicity, such as lower rates of IgH translocations in blacks(42–44) compared to 
whites. Similarly, TP53 mutations appear more frequently in individuals of European 
ancestry(45) than those of African ancestry. Also, genome-wide studies have yet to 
reveal susceptibility loci that uniquely associated with African ancestry and MM risk(18, 
19), adding to the gap in knowledge regarding the biological mechanism causing the 
disproportionately high MM incidence rate in individuals of African descent. 
When considering MM outcomes, the death rate in blacks is 2-fold higher than 
that of whites. This is due, in part, to the excessive MM incidence in black individuals 
and subsequently, a higher mortality rate. However, a large population-based study, 
using SEER registries of over 5,700 black and 28,000 white MM cases from 1973-
2005, showed a slightly favorable survival in blacks in years 1973-1993, with improved 
prognosis in whites between 1994-2005, around the time novel MM treatments were 
introduced clinically(46). The improvements in survival after 1994 were not as 
significant in blacks as it was in whites, suggesting that treatment access may have 
affected MM outcomes in black and white cases disproportionately. Moreover, a recent 
population-based study found that black patients survive longer than whites if both 
groups have access to similar treatments and autologous stem cell transplant 
(ASCT)(47). Additionally, black MGUS cases are diagnosed with fewer high-risk IgM 
MGUS than white MGUS patients(48). This and the lower occurrence rate of mutations 
like TP53 (associated with adverse prognosis) in those of African descent suggest a 
possible biological influence of slightly favorable outcomes in black patients. However, 
after adjusting for other prognostic covariates, the underlying cause of the minor 
improved survival in MM patients with African ancestry is unknown. 
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There is a well-founded highlight on African descendants when studying 
disparities in MM. However, less emphasis has been given to the fast-growing Hispanic 
population in the United States. Therefore, a significant portion of this thesis and the 
next section will focus on MM in the understudied Hispanic population.  
 
MM in Hispanics 
 
According to the Texas Tumor Registry, there are more Hispanics diagnosed 
with MM than non-Hispanic blacks in the last decade, even though Hispanics reported 
over half of the age-adjusted incidence rate compared to non-Hispanic black 
Texans (Table 1). Nonetheless, this fastest-growing minority group in Texas and the 
United States is overlooked in MM etiology and outcomes research. A PubMed search 
for “Hispanic AND myeloma” will yield only three SEER based studies on MM 
outcomes, underscoring the importance of investigating myeloma in this understudied 
population.  
Interestingly, Hispanics are diagnosed at a younger age (65 years), compared to 
blacks (66 years) and whites (71 years)(47), for unclear reasons.  
Other than the early onset of disease, little is known regarding MM development 
in this group. Therefore, research of MM etiology and clinical endpoints in Hispanics is 












Table 1. Texas Cancer Registry: New MM Cases, 2006 - 2016 
 
Population at Risk Cases Age-adjusted Rate 
Hispanic   106,516,575    3,843  6.3 
Non-Hispanic black      33,616,305    3,579  14.3 
Tumor Cancer Registry reports the number of MM cases in the Hispanic and non-














While clinical characteristics and cytogenetic abnormalities dictate outcomes for 
MM, data on genetic and clinical profiles of disease in Hispanics is limited in the 
literature. To date there exists no peer-reviewed study characterizing the clinical 
phenotype of MM in Hispanics. One abstract presented at the American Society of 
Hematology meeting in 2017 described disease presentation in 100 US Hispanic 
patients at diagnosis(49), reporting variation in clinical phenotypes, such as younger 
median age of diagnosis, favorable hemoglobin and creatinine levels, and lower 
occurrence of t(4:14) and monosomy 13 mutations when compared to white cases. 
This study provides evidence of distinct MM clinical features in Hispanics that require 
further investigation (Figure 1).  
When investigating the survival trends in Hispanics, the 1992-2007 SEER 
registries reported worse disease specific survival in Hispanics (2.7 years) than white 
(3.6 years), black (3.8 years), and Asian (4.1 years) patients(50). However, differences 
in prognosis by ethnicity has narrowed in recent years(51). A study based on a SEER-
Medicare dataset reported a comparable and even elevated disease-specific survival in 
Hispanics (5.4 years) compared to whites (4.5 years), pointing that Hispanics' previous 
adverse survival may be attributed to external factors such as treatment access. 
Indeed, treatment use and ASCT have increased among all ethnicities over time, but 
this increase has been more pronounced among white patients than black and 
Hispanic patients(47, 52). 
From lack of data in the literature, it is unclear how the mentioned differences in 
clinical phenotypes, overall survival, and early disease onset in Hispanics tie into the 
racial/ethnic disparity in MM risk and outcomes. To address the tremendous dearth of 
knowledge regarding MM in Hispanics, this proposal is designed to investigate the 
influence of genetic ancestry on MM risk and survival utilizing the robust clinical data 
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from MD Anderson’s diverse patient population. This study will be among the first to 
shed light on the genetic and clinical factors affecting of MM in the Hispanic population 
























Figure 1. Comparison of Baseline Clinical Characteristics Between Hispanic and 
White MM Cases 
An abstract during the American Society of Hematology meeting presented by Jain and 
colleagues describe the clinical features of Hispanic patients at diagnosis compared to 
white patients' baseline clinical characteristics collected by Kyle et al., 2003 and 
Fonseca et al., 2003. (Tania Jain, Rafael Fonseca, Ruqin Chen, Raj Patel, Prachi Jani, 
Veronica Gonzalez De La Calle, Zahara Meghji, James E. Hoffman, Alvaro J. Alencar, 
Kevin R Kelly, Vivek Roy, Taimur Sher, Asher A. Chanan-Khan, Sikander Ailawadhi; 
Racial Differences in Disease Characteristics: Understanding Multiple Myeloma in 
Hispanics. Blood 2017; 130 (Supplement 1): 864). I have been granted permission by 
the American Society of Hematology, provided by the Copyright Clearance Center, to 




Study Objective and Approach 
 
 
This thesis aims to identify links between genetic ancestry and MM susceptibility 
and outcomes in a diverse study population. Previous studies have identified genetic 
variations mediating risk, but the full spectrum of genetic factors remain unclear for this 
complex disease. The striking racial/ethnic disparity in MM susceptibility further alludes 
to the presence of genetic factors driving these differences. To begin understanding the 
roles of common germline variants and MM risk, we previously conducted a candidate 
pathway analysis focusing on variants within the Wnt/beta-catenin pathway. The 
rationale of this analysis was to assess the impact of genetic variants within pathways 
previously associated with MM risk. We will build on this discovery association study to 
investigate the genetic etiology of MM and how that may vary by race/ethnicity. 
  Moreover, studies have begun to interrogate the genetic basis for differences in 
survival and other clinical endpoints. However, these studies have been in populations 
of European descent and thus cannot adequately assess how genetic factors influence 
MM's outcomes by race/ethnicity. Furthermore, there is a gap in our understanding of 
the genetic etiology of MM and disease characteristics in Hispanics. Together, this 
underscores a great need for investigation into the genetic mediators of susceptibility 
and clinical outcomes of MM in multi-ethnic populations. By leveraging the robust 
medical records of the diverse patient population at MD Anderson Cancer Center, this 
proposal is designed to investigate the genetic influence on MM risk and outcomes of 
multi-ethnic subjects, with a special emphasis on Hispanics.  
 This study may provide a novel understanding of the genetic and clinical MM 
characteristics in the Hispanic patient population, while also identifying genetic 
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contributors to racial/ethnic disparities in MM susceptibility and outcomes. Therefore, 
we tested the central hypothesis that genetic ancestry differentially mediates MM 
susceptibility and outcomes in populations with varying ancestral backgrounds. 
Towards this, our approach is as follows: 
1. To Identify and confirm MM risk variants within the Wnt/beta-catenin pathway and 
ascertain if associations vary by race/ethnicity by building on a previous discovery 
analysis. In a prior study, we conducted a discovery candidate pathway analysis to 
identify variants associated with MM risk using a patient population from the MD 
Anderson Cancer Patient and Survivors Cohort (MDA-CPSC), seven variants 
associated with MM risk in a non-Hispanic white study population were identified.  
To replicate the findings and to also establish if these candidate variants differ 
by race/ethnicity, we conducted a cross-ethnic replication analysis on an additional 731 
self-identified non-Hispanic black, Hispanic, and non-Hispanic white MM cases, 
including 788 race/ethnicity matched controls. Genotyping was performed on the 
OncoArray platform that includes over 400,000 fixed genetic markers with a GWAS 
backbone for imputation. We also validated the significant association of the top 
candidate variants in a non-Hispanic white case-control dataset in collaboration with 
the Myeloma Working Group of the InterLymph Epidemiology Consortium. We then 
utilized in-silico informatics tools to evaluate the functional significance of variants. 
2. To examine the effect of European, African, and Amerindian (Indigenous American) 
genetic ancestry on MM susceptibility by conducting a case-control association 
analysis in 143 self-identified Hispanic, 211 non-Hispanic black, and 262 non-Hispanic 
white MM cases and 633 healthy controls. The inferred genetic ancestry of each study 
 16 
individual was calculated from a genome-wide genotyping dataset. Then, we analyzed 
the effect of each genetic ancestry on MM risk in the overall study population and also 
among self-identified Hispanic individuals. 
3. To characterize MM clinical phenotypes in Hispanics and analyze the differences in 
clinical profiles between race/ethnicities by utilizing the robust electronic medical 
records (EMR) of MD Anderson Cancer Center. From the EMR we abstracted 
extensive clinical and follow-up information including patient demographics, history of 
pre-malignancy, and clinical phenotypes such as subtypes, biomarkers, and diagnostic 
criteria. Extracted characteristics also included baseline cytogenetic/FISH/karyotype 
results for somatic mutations in high-risk patients and prognostic indicators such as 
beta-2-microglobulin (B2M), lactate dehydrogenase (LDH), and albumin levels.  
Also included in the abstraction were MM treatment regimens, treatment cycles, 
dates of response and relapses, death, and last date of follow up. We then conducted a 
cross-ethnic comparative analysis of abstracted clinical features and survival between 
self-identified Hispanics and non-Hispanic whites and non-Hispanic black patients.  
Furthermore, to investigate if differences in clinical phenotypes also vary by 
genetic ancestry, we analyzed the phenotypes by genetic ancestry. Such phenotypes 
included diagnostic and prognostic blood biomarkers, prior history of pre-malignancy 
and high-risk cytogenetic mutations (t(4;14), del(17/17p), t(14;16), t(14;20)). We also 
compared overall survival of patients, adjusting for appropriate prognostic covariates.  
This study will take steps towards improving MM risk assessment and cancer 
management in patients of diverse backgrounds in two ways: (1) filling the knowledge 
gap regarding the genetic contributors of MM susceptibility and outcomes in Hispanic 
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patients and (2) utilizing genetic ancestry instead of a self-reported ethnicity to better 
































Chapter 2: Genetic Variants Within the Wnt/beta-catenin Pathway 
Associated with MM Risk Vary by Race/Ethnicity 
 
This chapter includes data from Belachew, A. A., Wu X., Callender, R. A., Waller R., 
Orlowski, R. Z., Vachon, C. M., Camp, N. J., Zid, E., Hildebrandt, M. A. T. Genetic 
variants in the Wnt/beta-catenin signaling pathway as determinants of multiple 











Introduction and Study Objective  
 
Evidence suggests that the Wnt/beta-catenin pathway is linked to MM 
susceptibility(53). Additionally, genes within the canonical Wnt pathway have been 
shown to exhibit changes in expression in the bone micro-environment(54) leading to 
MM progression (55, 56). Furthermore, the conserved Wnt/beta-catenin pathway, a key 
player of cellular homeostatic actions(57), is also associated with self-renewal of 
cancer stem-like cells(58, 59). Hence, Wnt/beta-catenin pathway dysregulation is 
reported in the tumors of common cancers(60) and downstream effects of this pathway 
have been intensely studied as potential therapeutic targets(61, 62).  
Figure 2 illustrates the canonical Wnt pathway. During the “off” state of the 
canonical Wnt pathway, the beta-catenin destruction complex composed of 
ademomatosis polyposis coli (APC)/axin/glycogen synthase kinase-3 beta (GSK-3β) 
/casein kinase 1(CK1), phosphorylates beta-catenin leading to its ubiquitination and 
proteasomal degradation after binding to beta transducin repeat containing E3 ubiquitin 
protein ligase (β-TrCP). This action prevents beta-catenin from traveling from the 
cytosol to the nucleus, thus activating Wnt-targeted transcription factors.  
During the “on” state of this pathway, secreted glycoprotein Wnt ligand binds to 
the transmembrane G-coupled protein receptor Frizzled (FZD), along with its co-
receptor transmembrane low-density lipoprotein receptor-related Protein 5/6 (LRP 5/6), 
recruiting intracellular protein disheveled (DVL) to the cell membrane and consequently 
disrupting the beta-catenin destruction complex. This releases beta-catenin to 
translocate from the cytosol to the nucleus where it trans-activates transcription factors, 
such as T-cell factor/lymphoid enhancer factor (TCF/LEF), for the transcription of Wnt 
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target genes responsible for cellular proliferation, polarity, survival, and cell 
differentiation(63–65).  
Germline genetic studies have not yet ascertained the inherited genetic risk of 
MM development conferred by this pathway. Therefore, we aimed to identify the 
genetic mediators of MM susceptibility within the Wnt/beta-catenin pathway.  
To elucidate these genetic contributors, we performed discovery genotyping non-
Hispanic white MM case and control subjects from MD Anderson Cancer Center using 
variants identified from 26 core genes within the Wnt/beta-catenin pathway. We then 
verified our findings on an additional population of non-Hispanic white replication cases 
and controls from the same institute. External validation of replicated findings was 
conducted using existing genotyping data from the University of Utah and the 
University of California-San Francisco through the Myeloma Working Group (MWG) of 
the InterLymph Consortium(66). Given the evidence for racial/ethnic disparities in MM 
susceptibility, we further examined the association of these genetic variations with MM 





























Figure 2. Overview of the Canonical Wnt Signaling Pathway 
Canonical Wnt signaling pathway activation signaling cascade after the Wnt ligand 
binds to FZD and LRP5/6 co-receptors (left) and inactivation in absence of Wnt ligand 
with continual degradation of beta-catenin through ubiquitin-mediated proteolysis 












The overall design of the study is shown in Figure 3. For the discovery phase, 
269 self-reported non-Hispanic white patients diagnosed with MM were identified from 
the MD Anderson Cancer Patient and Survivors Cohort (MDA-CPSC)(67), a hospital-
based cancer patient cohort at The University of Texas MD Anderson Cancer Center. A 
total of 272 healthy non-Hispanic white control subjects, with no prior history of cancer, 
were recruited from Kelsey-Seybold Clinics(68). Cases and controls were matched by 
age (± 5 years) and sex (Table 2). Each subject provided peripheral blood as source of 
genomic DNA for genotyping conducted on a custom Illumina BeadXpress chip (San 
Diego, CA), which included 171 variants from 26 core genes of the Wnt/beta-catenin 
pathway identified from literature search and KEGG(69). Tagging variants (r2 > 0.8) 
from a 10 kb flanking region upstream and downstream within each core gene from the 
CEU HapMap population with a minor allele frequency > 5% were identified using 
Tagger(70). Written informed consent was provided by each patient and the study was 
approved by the Institutional Review Board of MD Anderson.  
Internal Replication Phase  
 
We selected an additional 292 non-Hispanic white MDA-CPSC MM cases from 
the MDA-CSPC and 331 healthy non-Hispanic white controls(68) matched by age and 
sex (Table 2) for internal replication of the seven variants identified in the discovery 
phase. Genotyping was performed on the genome-wide Illumina OncoArray followed by 
imputation to the 1000 Genome Project(71) using the Michigan Imputation Server(72). 
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Candidate variants were extracted from the dataset using PLINK(73) for replication 
analysis.   
External validation phase 
 
For the external validation phase, the two candidate variants from the internal 
replication analysis were extracted from existing genome wide association study 
(GWAS) data generated from 526 non-Hispanic white patients with MM and 878 non-
Hispanic white healthy control subjects (Table 2) from the University of Utah and 
University of California-San Francisco(66). Imputation of the external validation phase 
was performed using the Michigan Imputation Server(72) to the 1000 Genome 
Project(71). Written informed consent was provided by each patient and the study was 
approved by the respective Institutional Review Boards. 
Cross-Ethnic Internal Replication Phase  
 
Cross-ethnic internal replication of the seven variants from the discovery phase 
was conducted on self-reported 172 Hispanic and 267 non-Hispanic black MM cases 
from the MDA-CPSC. Control subjects (180 Hispanic and 277 non-Hispanic black)  
were selected from Kelsey-Seybold Clinics(68). Genotyping of the 49 Hispanic and 91 
non-Hispanic black MM cases, as well as 48 Hispanic and 90 non-Hispanic black 
control subjects, was performed using the Illumina BeadXpress genotyping chip (San 
Diego, CA). Genotyping of the remaining MM case/control samples was conducted on 
the Illumina OncoArray platform. The genotyping data from both platforms were 
combined and analyzed together. Written informed consent was provided by each 





For genotype quality control, variants deviating from the Hardy-Weinberg 
equilibrium in controls and those with call rates < 95% or minor allele frequency (MAF) 
< 0.01 were omitted from the analysis. Risk of MM for each variant was estimated 
using odds ratios (ORs) with 95% confidence intervals (95% CI) in multivariable logistic 
regression adjusting for age and sex. For each variant, analysis was conducted under 
the dominant, additive, or recessive model of inheritance (MOI) with the model with the 
lowest P-value reported.  Variants associated with MM risk with P < 0.05 during the 
discovery phase underwent bootstrap resampling of 1000 iteration to prioritize 
candidate variant selection. Variants consistently associated with MM risk with P < 0.05 
for 80% of the bootstraps were deemed candidates for replication. We also performed 
a meta-analysis for combined (fixed) effects of discovery-replication (same ethnicity)-
validation, as well as discovery-cross ethnic replication study groups. Statistical 
analysis was conducted using STATA 14 (Stata, College Station, TX).  
In-Silico Functional Prediction  
 
The location of variants in the genome was visualized using the UCSC genome 
browser(74). The regulatory and functional effects of genotyped variants and their 
proxies (r2 > 0.8) were determined using Haploreg4.1(75), Regulomedb(76), and 
LDLink(77) by annotating transcription regulators, as well as enhancer and promoter 
elements in lymphoblastoid cell lines. We also used the open-access expression trait 
loci (eQTL) browser (https://genenetwork.nl/bloodeqtlbrowser/) to identify eQTL of 






Figure 3. Study Design 
The flow chart shows the study design of the discovery, internal replication, and 
Myeloma Working Group (MWG) external validation in non-Hispanic white (NHW) study 
populations, along with the cross-ethnic internal replication phase in non-Hispanic black 











Characteristics of each study population are shown in Table 2. Males comprised 
a slight majority of the discovery cases (59.1%) and controls (59.6%), with higher 
representation in controls from the replication group (68.9%). The mean age of both 
MM cases and controls in the discovery study group was 60.8 years, and slightly older 
for the internal validation (62.4 years) and controls (61.6 years). Patients included in 
the MWG dataset had a median age of 60.0 for cases and 63.7 years for controls. The 
267 non-Hispanic black and 172 Hispanic patients with MM had a median age of 57.0 







































































































































































































































































































































































































































































































































Variants Associated with MM Risk in Non-Hispanic Whites  
 
Of the 171 variants analyzed in the discovery phase, seven were associated 
with MM risk with P value < 0.05 for over 80% of the bootstrap re-samplings (Table 3). 
These variants were deemed as candidate variants for internal replication in additional 
cases and controls from MD Anderson (Figure 3). Two of the candidate variants in 
LRP6, rs7966410 (OR: 0.57; 95% CI: 0.38-0.88; P = 9.90 x 10-3) and rs7956971 (OR: 
0.64; 95% CI: 0.44-0.95; P = 0.027) were also associated with reduced MM risk 
(rs7966410 – OR: 0.65; 95% CI: 0.44-0.97; P = 0.036; rs7956971 – OR: 0.69; 95% CI: 
0.48-0.99; P = 0.049) in the internal replication phase. Likewise, these results 
externally validated in the MWG dataset (LRP6:rs7966410 – OR: 0.57; 95% CI: 0.43-
0.76; P = 1.01 x 10-4; LRP6:rs7956971 – OR: 0.60; 95% CI: 0.45-0.79; P = 3.22 x 10-4). 
Meta-analysis across the three phases of this study for these two LRP6 variants 
demonstrated 42% and 37% reductions in risk of MM for rs7966410 and rs7956971, 
respectively (Figure 4). 
 
Cross-Ethnic Comparisons of Candidate Variants Associated with MM Risk 
 
Of the seven candidate variants identified in the discovery phase (Table 3), two 
variants (CSNK1D:rs9901910 and BTRC:rs7916830) replicated when genotyped in our 
cross-ethnic internal replication of non-Hispanic black and Hispanic populations. Similar 
to the discovery findings, CSNK1D:rs9901910 was associated with > 6-fold increased 
MM risk in non-Hispanic blacks (OR: 6.42; 95% CI: 2.47-16.7; P = 3.14 x 10-4) and over 
4-fold increased risk of MM in Hispanics (OR: 4.31; 95% CI: 1.83-10.1; P = 8.10 x 10-4) 
(Table 3). In addition, BTRC:rs7916830 conferred a 24% reduction in risk in the non-
Hispanic black population (OR: 0.76; 95% CI: 0.60-0.97; P = 0.028) that was similar in 
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effect to the reduced risk observed in the non-Hispanic white discovery phase. 
Although not statistically significant (P = 0.74), BTRC:rs7916830 was associated with a 
5% reduced risk in the Hispanic population. Consequently, the remaining of the seven 








































































































































































































































































































































































































































































































































































































































































































































































Figure 4. Genetic Variants in LRP6 Associated with Multiple Myeloma Risk in 
Non-Hispanic Whites  
The forest plot shows the estimated odds ratios (OR) with 95% confidence intervals 
(CI) for LRP6:rs7966410 and LRP6:rs7956971 risk variants in the non-Hispanic white 
population during the discovery, internal replication, and external validation, as well as 






Predicted Biological Function of Candidate Variants Associated with MM Risk 
 
 
Our analysis identified LRP6:rs7966410 as being associated with reduced MM 
risk in non-Hispanic whites. The functional consequence of this variant is unclear in the 
hematopoietic lineage based on in silico prediction analysis. However, we identified 
potential causal variants in high LD to the genotyped variant, including rs17819999 (r2 = 
0.97) located in a strong enhancer region of lymphoblastoid cell lines. Other variants in 
high LD (r2 ≥ 0.97), rs11054721, rs2417085, and rs10845496, were located in regions 
linked to tissue-specific epigenetic changes but were not shown to be linked to the 
hematopoietic cell lineage.  
The other MM susceptibility variant in LRP6, rs7956971, was also not predicted 
to be functional. We identified 13 variants in high LD (r2 ≥ 0.80) that were predicted to 
have functional effects within lymphoblastoid cell lines and other hematopoietic cell 
lineages. For instance, rs12823243 (r2 = 0.98), resides in a predicted binding site on 
LRP6 for several transcription factors, including IKAROS family zinc finger 1 (IKZF1), 
B-cell lymphoma/leukemia 11A (BCL11A), Spi-1 proto-oncogene (SPI1), and interferon 
regulatory factor 4 (IRF4), all of which play crucial role in the development of the 
hematologic lineage. rs7302808 (r2 = 0.83) is located 285 base pairs 5’ upstream of 
LRP6 and located within the transcription start site activator region for over 53 tissues, 
including those of hematologic lineage. Two variants in high LD, rs11054744 (r2 = 0.93) 
and rs12366664 (r2 = 0.97) were also located in regions of LRP6 associated with weak 
enhancer histone activity via methylation. Additional variants rs1819871, rs11054731, 
and, rs4763785 (r2 = 0.98) were located in transcription-factor binding sites associated 
with enhancer activity in lymphoblastoid cells lines. 
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CSNK1D encodes for the delta isoform of the casein kinase 1 involved in 
maintaining the “off” signal of the pathway. rs9901910 is intronic and located within an 
enhancer, as well as a genomic region linked to strong histone promoter/enhancer 
markers via methylation and acetylation activity in lymphoblastoid cell lines. A cis-eQTL 
for this variant was also reported for Dicarbonyl and L-xylulose Reductase (DCXR) in 
whole blood. This gene is located about 202 kb upstream of CSNK1D:rs9901910. A 
variant with high LD (r2 = 1) with rs9901910, rs4789846, was also predicted to serve as 
a cis-eQTL for Coiled-Coil Domain Containing 57(CCDC57) in lymphoblastoid cells. 
rs7916830 is located 2.7 kb upstream of the beta-transducin repeat containing E3 
ubiquitin protein ligase (BTRC) and is linked to gene regulation via polycomb gene 


















This study identified genetic variation within the Wnt/beta-catenin pathway as 
contributors to MM susceptibility and explored potential racial/ethnic differences in this 
risk. We discovered and validated rs7966410 and rs7956971 in LRP6 associated with 
reduced MM risk in non-Hispanic white study subjects. We also identified 
CSNK1D:rs9901910 to be associated with a 2- to 6-fold increased MM risk among all 
three racial/ethnic populations, further clarifying the underlying genetic contributors of 
MM susceptibility within the Wnt/beta-catenin pathway. An additional candidate variant, 
BTRC:rs7916830, was replicated in the non-Hispanic black population only, suggesting 
the variability in genetic etiology of MM risk by ancestry.  
The validated intronic variants, rs7966410 and rs7956971, are located in the 
gene for LRP6 encoding the low-density lipoprotein receptor-related protein-6, a 
transmembrane Wnt binding co-receptor. LRP5/6 in conjunction with the fizzled co-
receptor form the signaling complex with Wnt ligands to activate downstream signaling 
for beta-catenin stabilization and trans-activating Wnt target genes. Specifically related 
to MM, inhibition of the LRP5/6 co-receptor is reported to reduce tumor burden in MM 
mouse models(78). Additionally, molecular studies have demonstrated the LRP6 co-
receptor to play a direct role in Wnt inhibition activity by sequestering DKK1, an 
antagonist of the Wnt ligand, leading to the downregulation of the canonical Wnt 
signaling pathway(79, 80). This event is shown to disrupt the osteoclast/osteoblast 
homeostasis in the bone marrow, leading to bone destruction in MM patients(81). 
Some studies proposed anti-DKK1 antibody as a therapeutic agent to improve bone 
disease(82, 83), one of the four diagnostic criteria of MM(84), pointing LRP6 to be 
instrumental in MM risk as a possible regulator of bone homeostasis and bone disease.  
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Although there were no predicted functional consequences of rs7966410 and 
rs7956971 in the hematopoietic cell lineage, one possible causal variant, rs12823243, 
in high LD to rs7956971 pointed to functional effect through a transcription regulatory 
mechanism involving MYC. Rs12823243 resides on a predicted transcription factor 
binding site within LRP6 in lymphoblastoid cell lines for the transcription factors IKZF1 
and IRF4, both of which have been proven to play critical roles in MM progression. 
IKZF1, encoding the lymphoid transcription factor IKAROS(85), is normally activated 
during early lymphocyte differentiation and is a frequently mutated tumor suppressor 
gene in hematologic malignancies(86, 87). Downregulation of IKZF1 is shown to lead to 
the downregulation of the IKZF1 target genes, IRF4 and MYC. Reduced expression of 
the transcription factor IRF4 is also known to reduce MM cell viability, possibly through 
the downregulation of MYC(88).  Moreover, the MM chemotherapeutic drug 
lenalidomide has been shown to selectively degrade the IKZF1 transcription factor via 
E3 ubiquitin ligase activity(85) and induce cell toxicity through reduced expression of 
IRF4(89). It is important to point out that MYC mutations are reported in 15-20% of MM 
diagnoses(90), suggesting a potential regulatory mechanism between the causal 
variant in LRP6 and transcription factors IKZF1-IRF4 and MYC on MM risk.    
 CSNK1D:rs9901910 was associated with over 2-to-6-fold increase in MM risk 
across all populations. This variant is located within an enhancer region of over 22 
tissues, including those of hematologic lineage. CSNK1D encodes a monomeric 
serine/threonine kinase and interacts with dishevelled (DVL) within the beta-catenin 
destructive complex to regulate beta-catenin abundance in the cytoplasm(91). Although 
CSNK1D has not been studied in MM, other members of the highly conserved casein 
kinase family, CK2 and CK1α, have been shown to consistently sustain activation of 
well-known oncogenic signaling cascades, PI3K/AKT, JAK/STAT, and NF-κB, in MM 
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cell lines and mouse models(92, 93). Furthermore, loss of function or inhibition of CK2 
and CK1α has led to apoptosis and reduced MM cell survival as a result of impaired 
phosphorylation of these oncogenic signaling cascades. Hence, it would be useful to 
study the enhancer/promoter activity on which rs9901910 is located to elucidate if this 
effect also promotes activity of the mentioned oncogenic signaling cascades in MM.  
BTRC:rs7916830 was associated with MM risk in the non-Hispanic white 
discovery and the non-Hispanic black population. The protective effect associated with 
this variant is perhaps linked to polycomb gene repression that was predicted by our in 
silico analysis. Polycomb proteins that have gene silencing effect through epigenetic 
alterations(94) are also shown to undergo post-translational modification via ubiquitin 
mediated proteasome action(95). One study demonstrated the regulatory role of the E3 
ubiquitin protein ligase (β-TrCP) on a critical enzymatic subunit, enhancer of zeste 
homolog 2 (EZH2), of the Polycom repressor complex which tri-methylates H3K27 to 
mediate gene repression(96). By averting recognition of β-TrCP and hence 
degradation, stabilization of EZH2 through gain of function was shown to enhance tri-
methylation of the lysine tail of H3K27(me3) and promote B-cell lymphocyte 
pathogenesis. We also know that enhanced BTRC activity is positively correlated with 
MM progression(97), although the mode of tumorigenesis is unclear. In-vitro studies 
are therefore necessary to understand the tumorigenic significances of BTRC variants’ 
downstream epigenetic consequences in MM development.  
The strength of our study is the three-phase study design comprised of 
discovery, internal replication, external validation, and cross-ethnic internal replication 
phases. In silico functional prediction point to a biological inference of gene regulatory 
effect for the identified variants and proxies in the hematologic lineages. Nevertheless, 
in vivo studies are critical to understanding the mechanistic effects of these variants in 
 37 
MM development. A further strength is the inclusion of study participants from three 
different institutions and analysis of genetic risk across three different racial/ethnic 
populations. However, the study is limited in sample size from the non-Hispanic black 
and Hispanic populations that may hinder the ability to form a definitive conclusion on 
the significance of identified variants within these subgroups. We acknowledge that the 
selected variants in this study are from the CEU HapMap population, which is of 
European descent, and may not accurately tag the underlying genetic structure in the 
Hispanic and the non-Hispanic black populations. Nevertheless, given the scarcity of 
genotype data in the Hispanic patient population this study a solid stepping stone for 
further research to understand genetic variation within a diverse patient population 
associated with MM risk.  
In conclusion, this work identified candidate variants of MM for replication 
studies that have supporting functional consequences in silico. We also identified 
several variants associated with MM risk that vary by race/ethnicity. Previous studies 
show the Wnt/beta-catenin pathway as a key player in cancer progression. Our results 
may provide further insight into the biology of this pathway as well as its role in MM 
development. This study also serves as a platform for additional studies in 

































Introduction and Study Objective  
 
In Chapter 1, we highlighted the dearth of genetic and clinical studies of MM in 
Hispanics. We also described the well-established disparity in MM incidence by 
ancestral background that is yet to be studied in the Hispanic population. This chapter 
investigates if genetic ancestry mediates MM susceptibility in a multi-ethnic study 
population, emphasizing this relationship within the Hispanic population.  
Admixed human populations, like our Hispanic study subjects, have a non-
homogenous genetic inheritance from two or more insulated continental 
populations. Interbreeding between isolated parental populations create admixed 
generations through recombinant genetic events that allow their descendants to carry 
the original parental populations' chromosomal segments. In admixed individuals with a 
complex disease, chromosomal segments harboring the disease's susceptibility 
variants will show an excess of genetic ancestry from the parental population that 
carried the risk allele. Consequently, through admixture mapping, one can identify 
chromosomal regions that show an excess of ancestry from the high-risk parental 
population in individuals with the disease. Therefore, we will utilize admixture mapping 
to understand the relationship between genetic ancestry and MM risk as a complex 
disease. 
Admixture mapping can be performed by (1) local ancestry inference — tracing 
the parental ancestry of an individual from a particular chromosomal location or by  
(2) global ancestry inference — estimating the proportion of parental populations of an 
individual by averaging chromosomal segments of the entire genome of that individual.  
  We performed global admixture mapping to demonstrate the population 
structure of a multi-ethnic, case-control population. We then quantified MM risk based 
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on the proportion of genetic ancestry within our study population. Hispanics are a 
heterogeneous group comprising European, African, and Amerindian ancestry, 




























MM cases were diagnosed between 1981-2019 and selected from the MD 
Anderson Cancer Patient and Survivors Cohort (MDA-CPSC)(67). Patients were self-
identified as Hispanic (N = 143), non-Hispanic black (NHB; N = 211), and non-Hispanic 
white (NHW; N = 262). Healthy controls (N = 654) were identified from two approaches: 
(1) NHW and NHB controls were recruited from Kelsey-Seybold Clinics(98) and (2) 
Hispanic controls were selected from the Mexican American Mano a Mano Cohort(99). 
Hispanic control individuals were self-reported Mexican descendants who reside in the 
metropolitan Houston area(99). All controls were frequency matched to cases by age (± 
5 years), gender, and self-reported ethnicity (Table 4). We also collected our Hispanic 
cases' geographical origin using their MD Anderson medical records (Table 5). Written 
informed consent was provided by each patient, and the study was approved by the 




All case and control subjects provided peripheral blood as a source of genomic 
DNA for genotyping on the genome-wide Illumina OncoArray platform. Following QC 
and data cleaning, imputation was conducted to the HRC(71) (mapped to 
GRCh37/hg19) using the Michigan Imputation Server(72).  
 
Estimating Genetic Ancestry and Population Structure of the Study Population 
 
 ADMIXTURE(100) was used to evaluate the population structure and infer the 
study population's global ancestry. ADMIXTURE estimates ancestry in a model-based 
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manner from large autosomal SNP genotype datasets with a required pre-defined "K," 
for the number of assumed ancestries in the dataset. To choose the correct value of 
pre-defined K with the best predictive accuracy for estimating genetic ancestry, one 
can conduct cross-validation (CV) analysis for multiple Ks. A good value of K exhibits 
a low cross-validation error compared to other K values. Therefore, we performed 
cross-validation analysis on the OncoArray dataset for K1-K10 (CV error: K1: 
0.47455, K 2: 0.44339, K3: 0.43855, K4: 0.43841,  K5: 0.43771, K6: 0.43775, K7: 
0.43784, K8: 0.43799, K9: 0.43873, K10: 0.43842). We found K5 to have the lowest 
cross-validation error, and thus chose K = 5 to run unstructured ADMIXTURE on the 
Linkage Disequilibrium (LD) pruned (r2 > 0.2) OncoArray genotype dataset.   
Next, we conducted an independent Principle Component Analysis (PCA) on 
the OncoArray genotype dataset to visualize and confirm the ADMIXTURE findings. 
Through this step, ancestral outliers of admixed individuals can be identified for 
removal to minimize confounding. PCA can be a population stratification method by 
genotyped data and cluster individuals that share the greatest genetic similarities, i.e., 
genetic ancestry. LD pruned (r2 > 0.5) PCA was performed on the OncoArray 
genotype using the FlashPCA program(101). PCA and ADMIXTURE outputs were 
visualization using RStudio(102).  
Statistical Analysis  
 
Genotype quality control was performed by filtering call rates < 95% using 
PLINK. We then calculated the effect for every 10% increase of inferred genetic 
ancestry on MM risk using logistic regression models (adjusted for age and gender). 
Odds ratios (95% Cl) for MM risk by genetic ancestry for the overall population and 
stratified by self-identified NHW, NHB, and Hispanic ethnicity were reported. Moreover, 
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due to the admixed genetic heterogeneity, Hispanic subjects were further matched by 
their principal components. Next, the odds ratio (95% CI) of MM risk controlling for age 
and gender, after removing outliers identified through our PCA strategy were 
calculated. A p-value of < 0.05 was considered statistically significant. All statistical 
analysis was conducted using Stata 16 Software(103). 
Results  
 
Study Population  
 
For the NHW group, the median age of cases was higher (61.4 years) compared 
to NHB (57.5 years) and Hispanic (57.4 years) cases. Similar to Hispanics, males 
made up most of the cases (60.6%) and controls (62.1%) in NHWs. For the NHB 
group, female cases represented a slightly higher number (50.3%) and controls 
(50.5%). Table 4 describes the characteristics of the study population stratified by self-
identified race/ethnicity.  
Additionally, review of the electronic medical records (EMR) revealed that the 
majority of MM patients reside in Texas (83.9%), of which almost 22.5% come from 
Houston metropolitan area (Table 5). 4.9% of the patients live in New Mexico, and an 
additional 4.9% are residents of states other than Texas and New Mexico, including 
California, Tennessee, and Florida. International patients comprised only 6.3% of study 
cases, and a third of those came from Mexico. Together, 90.9% of self-reported 
Hispanic cases have Mexican heritage as many of Texan residents are of Mexican 
















Table 4. Study Population with Self-Identified Ethnicity (N = 1248)  
NHW (N = 533) NHB (N = 425) Hispanic (N = 290) 
  Cases Controls Cases Controls Cases Controls 
Total 261 272 211 214 143 147 
Gender 
      Male (%) 




















Age, mean (SD) 61.4 (9.2) 61.0 (8.5) 57.5 (10.8) 59.9 (8.3) 
 
57.4 (9.6) 59.6 (8.9) 
NHW = Non-Hispanic white 
NHB = Non-Hispanic black 


























Table 5. Self-Identified Hispanic Cases Place of Origin 








New Mexico  7 (4.9)   
Los Angeles  2 (1.4) 
 
Florida 4 (2.8) 
 
Tennessee 1 (0.7) 
 
Mexico 3 (2.1)   
**Non-US, Not Mexico 6 (4.2) 
 
Total  143 (100) 130 (90.9) 
**Non-US, Not Mexico  
Costa-Rica, N = 1 
Venezuela, N =1 
Honduras, N =1 
Puerto-Rico, N =1 
Colombia, N =1 
Ecuador N = 1 
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Population Structure of Study Subjects 
 
 
Figure 5 and Figure 6 demonstrates the study population's genetic population 
structure with the ancestral distribution of cases and controls stratified by self-reported 
ethnicity. In Figure 5, the y-axis represents the fraction of ancestry for K1-K5, for each 
of the 1,248 individuals shown in the x-axis. The self-reported NHWs were comprised 
of primarily K2 (purple) and K4 (orange) and a smaller portion of K3 (yellow), 
highlighting the genetic diversity of Europe (North-South gradient for example) that is 
being recapitulated here due to the immigration patterns of Europeans to the US. 
Because this thesis focused on the admixed minority subjects, we did not further 
classify K2, K4, and K3 by their geographical origin, but instead will condense these Ks 
as only European ancestry. Collectively, the average inferred European ancestry (K1, 
K4, and K2) in NHW cases and controls was (94.1%) and (97.8%), respectively. The 
highest European ancestral percentage in NHWs (K2) had a mean 53.7% for the cases 
and 68.1% for the controls. The second common inferred European ancestry (K4) in 
the NHW subjects reported an average of 22.6% in the cases and 19.5% in the 
controls.  
Furthermore, we observed that African descent (blue, K = 3) mapped primarily 
with the NHB study group, with an average of 80.3% inferred African ancestry in cases 
and 80.4% in controls. As expected, self-reported Hispanics were a three-way admixed 
population between European (K1, K2, K4), Amerindian (K5, green) ancestry, and a 
small percentage of African K3 heritage. Hispanic subjects comprised of primarily 
Amerindian (K5) ancestry, averaging 52.7% for controls, and 47.7% for cases. 
European ancestry made up an average of 46.8% in Hispanic cases and 45.6% in 
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controls. The average African ancestry was minimal in Hispanic cases (5.3%) and 
controls (1.7%).  
We successfully applied ADMIXTURE to determine the study subjects' 
population structure as the inferred genetic ancestry mapped to self-reported 
race/ethnicity. As expected, our self-identified NHW individuals were primarily 
European, whereas NHBs were primarily of African ancestry. Hispanics were a 
heterogeneous group consisting primarily of European and Amerindian ancestry. We 
also found a small sample size of African lineage (1 - 5%), which may preclude 
analysis in Hispanics by African ancestry. Furthermore, Figure 5 reveals individuals 
who harbor a different genetic lineage than their self-reported race/ethnicity—
highlighting the advantage of using quantified genetic ancestry instead of self-reporting 























Figure 5. Ancestral Percentages of Individuals in the MM Study Group by Self-
Identified Ethnicity 
 The MM study population (N = 1,248) stratified by self-reported non-Hispanic white 
(NHW), Non-Hispanic black (NHB), and Hispanic ethnicity map on to the inferred 
European - K1 (yellow), K2 (purple), K4 (orange), African - K3 (blue), and Amerindian - 




Figure 6. Ancestral Distributions of MM Cases and Controls by Self-Identified 
Ethnicity  
The box plot of MM cases and controls, further stratified by self-reported non-Hispanic 
white (NHW), Non-Hispanic black (NHB), and Hispanic individuals, illustrates the 
distribution and median proportion of the inferred genetic ancestry corresponding to 
European - K1 (yellow), K2 (purple), K4 (orange), African - K3 (blue), and Amerindian - 
K5 (green) origins.
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Association Between Genetic Ancestry and MM risk in the Overall Study 
Population  
 
We investigated the effect of a 10% increase in European, African, and 
Amerindian genetic ancestry on MM risk using logistic regression, unadjusted and 
adjusted for age and gender. For the overall population (Table 6), we identified a 
significant decreased MM risk associated with an increase of the K2 European 
ancestry. However, K2 is overrepresented in the NHW controls with the median K2 
percentage (~ 80%) compared to NHW cases (~ 50%) (Figure 6). Therefore, K2 
matching between cases and controls is required to conclude that K2 European 































Association Between Genetic Ancestry and MM Risk by Self-Identified Ethnicity  
  
After stratification by self-reported ethnicity, we identified that the K2 European 
ancestry was significantly associated with a decreased MM risk among NHW 
Table 6. MM Risk in the Overall (N = 1248) Study Population by Inferred Ancestry 
   Unadjusted OR (95% CI) P-value  
        K1 (European) 1.05 (0.95-1.15) 0.34 
        K2 (European)  0.95 (0.93-0.99) 0.019 
    K3 (African) 1.02 (0.99-1.05) 0.16 
        K4 (European) 1.03 (0.97-1.09) 0.30 
          K5 (Amerindian) 0.98 (0.93-1.03) 0.47 
  Adjusted (age and gender)  
        K1 (European) 1.05 (0.95-1.15) 0.33 
        K2 (European)  0.96 (0.93-0.99) 0.039 
    K3 (African) 1.02 (0.98-1.04) 0.23 
        K4 (European) 1.03 (0.97-1.09) 0.26 
          K5 (Amerindian) 0.97 (0.92-1.03) 0.41 
OR is the effect size for MM risk for every 10% increase of a given ancestral fraction (K1-
K5), unadjusted and adjusted for age and gender 
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individuals. Although not statistically significant, African ancestry increased MM risk 
over 2-fold in NHWs. Inferred Amerindian ancestry was also associated with an 
increase in MM risk in NHW study groups; however, this effect was not significant 
(Table 7)  
For the NHBs study subjects (Table 8), European ancestry was associated with 
decreased MM risk, although not statistically significant. Characteristically, a 10% 
increase in African lineage indicated a significant 15% increase in MM risk, echoing the 
hypothesis that elevated African genetic ancestry imposed an increase in MM 
susceptibility. Increasing Amerindian ancestry suggested an increase in MM risk in 
NHBs; however, with no statistical significance.   
When considering self-identified Hispanics (Table 9), we identified a significant 
(P = 0.025) 12% reduced risk of MM for every 10% increase of Amerindian Ancestry, 
suggesting that Amerindian heritage may be protective of MM risk. Albeit not 
statistically significant, we identified that MM risk increased by 4 - 6% for increasing 


















Table 7. MM Risk in NHW (N = 533) Study Population by Ancestry 
   Unadjusted OR (95% CI) P-value  
        K1 (European) 1.06 (0.95-1.12) 0.27 
        K2 (European)  0.91 (0.86-0.97) 0.002 
    K3 (African) 2.32 (0.81-6.66) 0.11 
        K4 (European) 1.04 (0.97-1.12) 0.22 
          K5 (Amerindian) 1.19 (0.95-1.50) 0.12 
  Adjusted (age and gender)  
        K1 (European) 1.07 (0.95-1.20) 0.33 
        K2 (European)  0.91 (0.87-0.97) 0.002 
    K3 (African) 2.39 (0.81-7.05) 0.11 
        K4 (European) 1.04 (0.97-1.12) 0.22 
          K5 (Amerindian) 1.19 (0.95-1.51) 0.12 
OR is the effect size for MM risk for every 10% increase of a given 





























Table 8. MM Risk in NHB (N = 425) Study Population by Ancestry 
   Unadjusted OR (95% CI) P-value  
        K1 (European) 0.73 (0.38-1.40) 0.35 
        K2 (European)  0.88 (0.73-1.06) 0.19 
    K3 (African) 1.13 (0.99-1.30) 0.056 
        K4 (European) 0.83 (0.60-1.14) 0.30 
          K5 (Amerindian) 1.00 (0.53-1.87) 0.98 
  Adjusted (age and gender)  
        K1 (European) 0.69 (0.36-1.33) 0.27 
        K2 (European)  0.86 (0.71-1.05) 0.15 
    K3 (African) 1.15 (1.00-1.32) 0.040 
        K4 (European) 0.82 (0.59-1.15) 0.26 
          K5 (Amerindian) 0.92 (0.49-1.72) 0.79 
OR is the effect size for MM risk for every 10% increase of a given 








Table 9. MM Risk in Hispanic (N = 290) Study Population by Ancestry 
   Unadjusted OR (95% CI) P-value  
        K1 (European) 1.06 (0.85-1.31) 0.59 
        K2 (European)  0.98 (0.86-1.11) 0.79 
    K3 (African) 5.09 (0.68-37.7) 0.11 
        K4 (European) 1.05 (0.92-1.20) 0.45 
          K5 (Amerindian) 0.88 (0.79-0.98) 0.024 
  Adjusted (age and gender)  
        K1 (European) 1.06 (0.85-1.32) 0.57 
        K2 (European)  0.99 (0.87-1.13) 0.95 
    K3 (African) 5.35 (0.69-41.2) 0.11 
        K4 (European) 1.04 (0.91-1.19) 0.50 
          K5 (Amerindian) 0.88 (0.79-0.98) 0.025 
OR is the effect size for MM risk for every 10% increase of a given 













Principle Component Analysis in Self-Reported Hispanics  
 
 
To match admixed cases and controls by their genetic principal components, we 
performed a principal component analysis on the LD pruned OncoArray genotype 
dataset in Hispanics. We include the place of residence for each case (Table 5) when 
visualizing PCA results to discern if the outliers were from international patients.   
Figure 7 shows the plot of the principal components (PC1 vs PC2) of the 
Hispanics study subjects. The population structure of Hispanic cases (orange) and 
controls (blue) were distributed almost evenly between the European and Amerindian 
genetic ancestry, with 11 Hispanic outlier cases. When cross-referencing the genetic 
ancestry of the 11 outliers, we found that those cases exhibited the highest proportion 
of African lineage. Therefore, PC1 corresponded to African genetic ancestry.  
We then removed the 11 outliers and re-ran the PCA analysis on the remaining 
279 Hispanics study subjects to match cases and controls. PCA results are illustrated 
in Figure 8, Figure 9, and Figure 10. With removed individuals of primarily African 
descents, Figure 8 shows an almost perfect match of cases and controls by principal 
components corresponding to European and Amerindian ancestry. We did, however, 
identify potential outliers e.g., Texas resident case of PC2 > 0.25.  
Therefore, we plotted PC2 vs. PC3 (Figure 9) and PC3 vs. PC4 in Figure 10, 
which uncovered primarily international case outliers from Mexico, Honduras, and 
Puerto Rico. After removing the seven other outliers circled out in Figure 10, we have a 
closely matched population of Hispanic cases and controls by their genetic principal 








Figure 7. Principal Component Analysis Result for Hispanics (PC1 vs PC2, N = 
290)  
Population structure of N = 290 Hispanic cases (orange) and controls (blue) is plotted 











Figure 8. Principal Component Analysis Result for Hispanics (PC1 vs PC2, N = 
279)  
Population structure of N = 279 Hispanic cases (orange), and controls (blue) is plotted 























Figure 9. Principal Component Analysis Result for Hispanics (PC2 vs PC3, N = 
279)  
Population structure of N = 279 Hispanic cases (orange), and controls (blue) is plotted 










Figure 10. Principal Component Analysis Result for Hispanics (PC3 vs PC4, N = 
279)  
Population structure of N = 279 Hispanic cases (orange), and controls (blue) is plotted 








MM Risk in Self-Identified Hispanics after PCA Matching  
 
The effect size of a 10% increase in ancestry after removing the initial 11 outlier 
cases is described in Table 10. The odds ratio of MM risk after removing the additional 
seven outlier Hispanic individuals (total, N = 18) is also shown in Table 11. Although 
the protective effect of Amerindian ancestry remained, the statistical significance was 



























Table 10. MM Risk in PC Matched Hispanic (N = 279) Study Population by Ancestry 
   Unadjusted OR (95% CI) P-value  
        K1 (European) 1.06 (0.85-1.32) 0.55 
        K2 (European)  1.01 (0.89-1.15) 0.84 
    K3 (African) 1.11 (0.06-17.9) 0.94 
        K4 (European) 1.05 (0.92-1.20) 0.46 
          K5 (Amerindian) 0.92 (0.82-1.03) 0.15 
  Adjusted (age and gender)  
        K1 (European) 1.07 (0.86-1.33) 0.54 
        K2 (European)  1.02 (0.89-1.16) 0.71 
    K3 (African) 1.23 (0.076-20.0) 0.88 
        K4 (European) 1.04 (0.91-1.99) 0.50 
          K5 (Amerindian) 0.92 (0.82-1.03) 0.15 
OR is the effect size for MM risk for every 10% increase of a given ancestral fraction (K1-

















Table 11. MM Risk in PC Matched Hispanic (N = 272) Study Population by Ancestry 
   Unadjusted OR (95% CI) P-value  
        K1 (European) 0.90 (0.69-1.17) 0.46 
        K2 (European)  1.04 (0.91-1.18) 0.54 
    K3 (African) 1.17 (0.06-19.0) 0.90 
        K4 (European) 0.99 (0.86-1.53) 0.98 
          K5 (Amerindian) 0.96 (0.86-1.08) 0.57 
  Adjusted (age and gender)  
        K1 (European) 0.91 (0.70-1.19) 0.51 
        K2 (European)  1.05 (0.92-1.20) 0.42 
    K3 (African) 1.29 (0.080-21.0) 0.85 
        K4 (European) 0.99 (0.86-1.14) 0.91 
          K5 (Amerindian) 0.99 (0.85-1.08) 0.56 
OR is the effect size for MM risk for every 10% increase of a given ancestral fraction (K1-














This chapter identified the differential risk of MM by genetic ancestry and 
elucidated that Amerindian ancestry may have protective associations for MM risk in 
Hispanics. In our overall study population, we found a trend of increased MM risk by 
increasing African ancestry and a decrease of MM risk by increasing European and 
Amerindian ancestry.  
The influence of genetic ancestry on MM risk was more pronounced when we 
stratified our subjects by self-reported race/ethnicity. Consequently, we reported an 8% 
significantly decreased MM risk by a 10% increase of the predominant K2 European 
ancestry in NHWs.  We also identified a significantly enhanced MM risk by increasing 
African ancestry in our NHB study subjects (African ancestry; OR: 1.15; 95% CI: 1.00-
1.32; P = 0.040). The increase of MM risk in African descents is well documented in the 
literature(105, 106), which aligned with our findings. We also found a 12% decreased 
MM risk for every 10% increase of Amerindian ancestry (P = 0.025), suggesting a 
protective effect of MM risk for admixed populations that carry a high percentage of 
Amerindian ancestry as opposed to those of European/Spanish ancestry.  
We know that our Hispanic control population is predominately of Mexican 
descent and therefore have a higher proportion of Amerindian ancestry than most US 
Hispanic populations. However, we do not have background information for the 
Hispanic patient population at MD Anderson. Therefore, we controlled for the potential 
ancestral mismatch of our heterogeneous Hispanic cases and controls to see the 
protective association using principal component analysis. After PC adjustment by 
principal genetic components and controlling for ancestral differences between the 
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Hispanic case and control populations, the significant effect of Amerindian ancestry 
was attenuated.   
Albeit not statically significant, Amerindian consistently remained protective of 
MM risk after PC matching for a 10% increase of K5 with a wide confidence interval 
(0.85 to 1.08) (Table 11). Additionally, the most recent SEER data shows that the 
incidence rate of US Hispanics is slightly lower than NHWs, and the incidence rate of 
American Indians and Alaskan residents are almost half of the general population. 
Interestingly, one nested case-control study of California Hispanic farmworkers derived 
from a multi-ethnic cohort study of 130,000 farmers, revealed an elevated risk of 
incidence in hematological malignancies, i.e., leukemia and non-Hodgkin lymphoma, 
particularly in female workers exposed to pesticides. However, an increase in MM 
incidence was not present in this study group(107). Farming is a known MM 
occupational hazard(108); therefore, it is still plausible that Amerindian ancestry is 
somewhat protective of MM risk. However, additional validation studies on a larger 
Hispanic study population is essential to determine if Amerindian ancestry is indeed 
associated with a reduction of MM risk. 
Overall, the cancer incidence rate is lower in Hispanics than the NHW and NHB 
populations(109). However, infectious based cancers and cancer associated with 
diabetes and obesity, such as gastrointestinal and liver cancers, are becoming more 
prevalent in Hispanics(109). Furthermore, the inverse relationship between Amerindian 
genetic ancestry and risk of incidence has been reported in common cancers like 
prostate and breast cancer, after adjusting for socioeconomics and lifestyle. One study 
that confirmed this inverse relationship of breast cancer incidence and Native American 
heritage in postmenopausal Hispanic women found that those with the highest 
proportion of Native American ancestry (71–100%) carried risk loci on IkBKB, mTOR, 
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PDK2, PRKAA1, RPS6KA2, and TSC1. In contrast, genes NFκB1, PTEN, and 
RPS6KA2 were associated with Hispanics, with over 70% of European ancestry(110). 
Also, Latin American women report a high incidence of aggressive HER2+ breast 
cancer. This association also trends with elevated Amerindian ancestry(111), 
analogous to our findings that ancestral background is associated with differential 
cancer risk.  
We do not have genetic data on the relationship between MM and Hispanics in 
the literature. However, one study reported that Hispanic children with Native American 
ancestry over 10% are at a higher risk of relapse of B-cell acute lymphoblastic 
leukemia (ALL), a hematological malignancy closely related to MM(112). In parallel,  
risk loci rs3731217 and rs3824662 partially explain ALL relapse in patients that harbor 
high Native American genetic lineage(113, 114). Likewise, genome-wide studies or 
local admixture mapping in a larger Hispanic patient population may identify genetic 
loci that mediate the protective effect of MM. Nevertheless, extensive research is vital 
to narrow the gaps in our knowledge on the effects of genetic ancestry in MM 
susceptibility in these subgroups.  
There are limitations to using unstructured ADMIXTURE. To navigate this, we 
previously projected our inferred ancestry results to three publicly available HapMap3 
reference populations(115). The reference populations selected include (1) European 
ancestry — (CEU: Utah residents with Northern and Western European) (2) African 
ancestry — (YRI: Yoruba in Ibadan, Nigeria), and (3) Mexican ancestry — (MXL: 
Mexican ancestry in Los Angeles). Individuals genotyped for the MXL reference 
population identified themselves as having at least 3 out of 4 grandparents born in 
Mexico, potentially matching Mexican ancestry to our self-identified Hispanic study 
group.  
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We also performed an extensive literature search to identify ancestry informative 
SNP markers that exhibit substantial allele frequency differences between European, 
Amerindian, and African reference populations to precisely estimate the population 
structure for our admixed study subjects. From this, we identified two groups in the 
literature with a robust AIMs panel(116, 117). One reported 2,120 AIMs derived from 
reference populations genotype of European origins, as well as Mesoamericans (Maya 
and Nahua from Mexico), South Americans (Aymara/Quechua from Bolivia and 
Quechua from Peru), West African (YRI), and East Asians (populations from China and 
Japan). The other AIMs panel (N = 975) was assembled using the HapMap3 reference 
European populations (CEU, Utah residents from northern and western European 
Populations), African populations (YRI, Yoruba in Ibadan, Nigeria and LWK, Luhya in 
Webuye, Kenya), and Pima Indians in Arizona (PIMA, full heritage Pima or Tohono 
O'odham individuals or combination of the two tribes)(116).  
We then extracted these AIMs from our study population's imputed dataset with 
high QC cutoff (average r2 = 0.99 and individual call rate > 0.95). Next, we simulated 
Amerindian reference genotype drawing on genotypes from the 1000 Genomes 
reference population (CEU, YRI)(118) and by calculating binomial distribution with 
success probability equal to the allele frequencies of extracted AIM SNPs from 
Mesoamerican and PIMA source population. Afterward, we ran unstructured 
ADMIXTURE on the overall study population using the simulated AIMs panel to 
determine our study group’s population structure and estimated the genetic ancestry of 
admixed individuals in a precise manner. 
Unfortunately, neither of these strategies, i.e., using CEU, YRI, and MXL 
ancestry as a reference population and using simulated Amerindian AIMs, were 
feasible. The MXL reference population was admixed within itself and introduced noise 
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in the study samples' population structure. Moreover, we found differing ancestral 
estimates from simulated AIMs than the assumed ancestral fraction of our admixed 
study individuals. For instance, our self-identified Hispanics reported a 32% - 36% 
Amerindian ancestry and about 60% European ancestry using the simulated AIMs. 
Past population structure analysis has shown Amerindian lineage (51% - 56%) in those 
with Mexican lineage followed by European ancestry (40% - 45%) and a small share of 
African descent (2% - 5%)(119). Given that our Hispanic subjects are primarily Mexican 
descendants residing in Texas, we postulate that the direct genotype ancestry (K = 5) 
estimate of 47 - 52% Amerindian followed by 46 - 47% European and 1 - 5% African 
was a more accurate predictor. 
 A potential explanation for this inconsistency may be due to our AIMs derived 
reference populations, i.e., Mesoamericans (Maya and Nahua from Mexico) and PIMA 
Indians. These populations may have been too specific and isolated as they only 
captured a smaller subset of Amerindian ancestry in our heterogeneous Hispanic study 
groups. Another explanation may attribute to the imputation platform, i.e., the 1,000 
Genomes Project which is underrepresented in its admixed reference population, 
potentially skewing our ancestry estimate towards European ancestry.  
We acknowledge that the probability of finding specific AIMs in direct genotype 
platforms is low. That is why we extracted our AIMs from the imputed dataset with 22 
million+ SNPs. However, to mitigate this discrepancy, we suggest that future 
investigators impute direct genotype on platforms such as TOPMed(120) before 
ancestral estimation. TOPMed contains reference sequencing data of over 100,000 
admixed individuals and has also identified risk loci unique to Hispanics that would 
have otherwise been genome-wide insignificant on the 1,000 Genomes Project.  
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Overall, the unstructured K = 5 ADMIXTURE approach was the most viable 
method to ascertain our study subjects' population structure. From this, we found 
suggestive evidence that Amerindian ancestry may be protective of MM susceptibility 
with a recommendation for further investigation. We also confirmed the direct 
relationship between increasing African genetic lineage and increasing MM risk in 





























Chapter 4: Genetic Ancestry Mediates MM Disease Types and 














Introduction and Study Objective 
 
MM Evaluation and Clinical Presentation  
 
As described in Chapter 1, MM is a heterogeneous disease characterized by the 
uncontrolled production of plasma cells and the presence of one or more CRAB 
symptoms. Plasma cells produce excessive immunoglobulin (Ig) heavy chains (G, A, D, 
E, or M) and one type of light chain (kappa or lambda). IgG is the most common 
subtype (54%), followed by IgA (21%) and light chain restricted (16%)(121). 
For MM diagnosis, the necessary clinical workup includes a bone marrow biopsy 
to identify excessive CD138+ plasma cells and cytogenetics/FISH analysis. FISH 
probes detect chromosomal abnormalities such as hyperdiploidy and the presence of 
high-risk mutations i.e., del17p, t(4;14), t(11;14), and t(14;16). Additional evaluation for 
suspected MM includes a complete blood count and serum biomarkers, i.e., lactate 
dehydrogenase, creatinine, beta-2-microglobulin, and albumin. In addition, serum 
protein electrophoresis is used to quantify M paraproteins and identify Ig subtypes and 
serum free light chains. Urine studies include an immunofixation and a 24-hour urine 
protein test to detect Bence Jones(122). Radio-imaging is also essential to detect lytic 
lesions and compression fractures that cause bone disease(121, 123).  
The three staging systems that have been developed for MM include the Durie-
Salmon system, the International Staging System (ISS), and the Revised International 
Staging Symptoms (R-ISS). The ISS and R-ISS staging criteria put forward by the 
International Myeloma Working Group are the most recent prognosis identifiers. Figure 









Figure 11. MM Diagnosis and Prognostic Biomarkers  
MM diagnosis is based on > 10% of plasma cells in the bone marrow in addition to one 
or more of the MM CRAB symptoms — diagnosed from serum calcium levels, 
creatinine, hemoglobin levels, and radio imaging results for detecting bone lesions and 
pathologic fractures. MM prognosis and stage classification is established by serum 
beta-2-microglobulin, albumin, and lactate dehydrogenase levels, as well as the 





In Chapter 3, we illustrated that genetic ancestry contributes to MM susceptibility 
by ethnicity. In this Chapter we analyzed the patterns of clinical phenotypes that 
characterize disease subtypes that may also drive prognosis in Hispanics. In addition, 
we utilized the genetic ancestry information from Chapter 3 to ascertain if distinct 
patterns of clinical profiles in Hispanics also correlate with European, African, or 
Amerindian genetic ancestry.  
We leveraged the robust medical records of the diverse patient population at MD 
Anderson to determine patterns of MM clinical characteristics and identify differences in 
clinical features by self-reported race/ethnicity. Next, we used genetic ancestry 
information to find differences in MM outcomes by ancestral background. MM 
outcomes studied by genetic ancestry included occurrence rate of somatic 
mutations/high-risk profiles, MGUS/SMM diagnoses, and survival in the overall study 
population. 
The objective of this Chapter is to identify important clinical features that are 
enriched in Hispanic patients, while also using this information to uncover differences of 
MM outcome by race/ethnicity and genetic ancestry. Therefore, we designed a study to 
ascertain unique MM disease features in Hispanics and compared them with a multi-
ethnic MM patient population. Through the increased knowledge of the clinical 
presentation and course of disease in Hispanic cases this study may help to provide 






Study Design and Methods  
 
 
Study Population, Genotype, and Ancestry Analysis  
 
The study populations for this analysis were the N = 615 MM patients described 
in Chapter 3 and Table 4. Genotyping and ancestry inference of the MM study 
populations are also described in Chapter 3 Study Design and Materials and displayed 
in Figure 5 and 6. 
Clinical Data Collection 
 
For clinical data collection from the MD Anderson electronic medical records, we 
created a comprehensive 9-paged customized abstraction form with N > 100 variable in 
collaboration with Dr. Elisabet Manasanch (Department of Lymphoma/Myeloma). 
Information gathered from the abstraction form included demographics, history of MM 
precursors, MM immunoglobulin (Ig) subtypes, cytogenetics karyotype, FISH data, and 
lytic lesions detected by X-ray, PET CT, or MRI. Additional data included baseline 
diagnostic and prognostic indicators from the serum, urine and the bone marrow clinical 
assays, in addition to serum and urine biomarker levels indicating treatment response. 
We also abstracted treatment regimen, dates of treatment, clinical indicators of relapse 
and response, dates of follow up, dates of death.  
Statistical Analysis  
 
To investigate the clinical features of Hispanic MM patients in comparison to 
NHW and NHB patients, we performed the appropriate chi-square or student’s t-test for 
baseline categorical and continuous biomarkers, respectively. Risk of MM binary 
outcomes (previous reporting of MGUS/SMM and occurrence of high risk cytogenetic 
mutations) by genetic ancestry (African (K3), European (K1, K2, K4), or Amerindian 
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(K5) was assessed using logistic regression with corresponding odds ratios (ORs) and 
95% confidence intervals (CIs).  
Cox proportional hazards model adjusted for age, sex, and high-risk 
cytogenetics was used to assess overall survival as a function of race/ethnicity. 
Additionally, survival hazard ratio (HR with 95% CI) was performed for every 10% 
increase of genetic ancestry as described in Chapter 3. Recruitment for this study 
began in 2010, even if those patients had a history of MM prior to 2010. Therefore, to 
avoid prevalence confounding in our survival analysis, we divided the patients into two 
groups; those diagnosed prior 2010 and after 2010. Kaplan–Meier survival function and 
corresponding log-rank tests were used to plot overall survival stratified by 
race/ethnicity and diagnosis year (prior or after year 2010). Survival time was defined 
as the duration from the date of diagnosis to the date of death or last follow-up visit. 
P values < 0.05 were considered statistically significant. Statistical analysis was 
performed using GraphPad Software (San Diego, California) and Stata software 















The clinical profile of our study subjects is shown in Table 12. Some defining 
features of Hispanics include a significantly younger age of diagnosis (57.4 years, P = 
0.003), compared to NHW (61.4), but similar to NHB (57.5 years) patients. Additionally, 
we found a lower prevalence of MGUS and/or SMM in Hispanics (8.4%) compared to 
NHW (18.8%) and NHB (16.1%). For Hispanics, IgG comprised the majority (53.8%), 
followed by IgA and light chain restricted (21.6%) and IgD (1.4%). From this, we 
observed that the IgA subtype occurs at a slightly higher rate in Hispanics compared to 
NHW (18.8%) and NHB (13.7%). Hispanics have an intermediate percentage of high-
risk cytogenetics abnormalities (11.8%) between NHW (13.0%) and NHW (7.1%). 
Overall, we observed some variation of clinical phenotype Hispanics when compared to 















Table 12. Characteristics of Study Population by Self-Identified Ethnicity (N = 615) 
    Hispanic   NHB NHW 
Total: 143   211 261 
Dates of diagnosis:  1998 - 2019  1981 - 2019 2001 - 2019 
Gender:       
     Male (%) 81 (56.6)   105 (49.7) 158 (60.5) 
     Female (%)  62 (43.4)   106 (50.3) 103 (39.4) 
Median age of diagnosis:   
 
57.4 
(29.0 - 82.0)  
57.5 
(28.0 - 87.0) 
61.4 
(36.0 - 87.0) 
Previous case of MGUS/SMM (%): 
 12 (8.4)  34 (16.1) 49 (18.8) 





















Risk by cytogenetic abnormalities (%): 
     High risk (%) 
     Standard risk (%) 
     N/A (%) 
17 (11.8)  
69 (48.3) 







High risk cytogenetic abnormalities: t(4;14), t(14;16), t(14;20), del(17/17p)  
MGUS: Monoclonal gammopathy of unknown significance  
SMM: Smoldering multiple myeloma  
NHB: Non-Hispanic black  
NHW: Non-Hispanic white  









Clinical Phenotype by Genetic Ancestry  
 
We calculated the relationship between genetic ancestry and clinical features 
exhibiting differences by self-identified ethnicity in our study subjects and those that 
have previously indicated differential association by race/ethnicity. Chapter 1 described 
that MGUS/SMM prevalence and chromosomal abnormalities occur with a varying 
degree by ancestry. 
In the previous section, we discovered a higher frequency of high-risk 
cytogenetic mutations in self-identified NHWs, followed by Hispanics and NHBs. Some 
studies have also indicated a greater occurrence of chromosomal abnormalities in 
individuals of European descent(45, 105). Genetic ancestry results in Chapter 3 
indicated that Hispanics were a distribution of inferred European (~40%) and 
Amerindian (~50%) ancestry. Therefore, to determine if the European ancestry is a 
driving factor of the higher frequency of the high-risk cytogenetic mutations in Hispanics 
and NHW patients, we calculated the odds ratio of these mutations in patients with > 
40% inferred European ancestry and cases with > 50% Amerindian ancestry.  
Consequently, we discovered that Hispanics having > 40% European ancestry 
showed over 3-fold increased risk of these mutations (P = 0.036). We also found a 
borderline significant inverse relationship between Amerindian ancestry and high-risk 
cytogenetic mutations in Hispanics (OR: 0.33; 95% CI: 0.11-1.03; P = 0.055) in this 
group. When calculating the risk of mentioned genetic abnormalities in the overall study 
group, patients with > 40% European ancestry also exhibited a 1.70-fold increased risk 
of these mutations (P = 0.056) with no significant association by Amerindian ancestry 
(Table 13). This suggests that European ancestry was the driving factor for high-risk 
cytogenetics in the Hispanic, as well as overall study subjects.  
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We used the same method to determine if the prior case of MGUS/SMM is 
mediated by European or Amerindian ancestry. However, we did not find any 
significant association between MGUS/SMM prevalence by European or Amerindian 

















































Study Group OR (95% CI) P-value 
Overall (N = 378) 
   European > 40% 







Hispanic (N = 86) 
   European > 40% 







OR is the risk of occurrence of one or more of the  t(4;14), 
t(14;16), t(14;20), del(17/17p) abnormalities for individuals 
with > 40% European and Amerindian ancestry in the 





























Study Group *OR (95% CI) P-value 
Overall (N = 615) 
   European > 40% 







Hispanic (N = 413) 
   European > 40% 







OR is the risk of a prior diagnosis of MGUS and/or 
SMM for individuals with > 40% European and 
Amerindian ancestry for the overall study population 
and Hispanics only. *OR is adjusted for age 
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Diagnostic and Prognostic Clinical Biomarkers  
 
 
We compared the diagnostic and prognostic marker levels of Hispanic patients 
to NHW and NSW study subjects at diagnosis illustrated in Figures 12 and 13. When 
considering diagnostic blood markers, we observed a significantly lower hemoglobin 
level in NHB patients (P = 0.019) compared to Hispanics with no significant differences 
compared to NHWs (Figure 12A). A low hemoglobin level < 10.0 g/dL is suggestive of 
anemia, one of the CRAB symptoms. 
A high creatinine level is also an indicator of CRAB manifestation in MM patients 
through renal failure. We found a significant elevation of median creatinine levels (P = 
0.035) NHB patients compared to Hispanics. However, differences in median creatinine 
levels were not significant different between Hispanics and NHW cases (Figure 12B).  
The percentage of clonal plasma cells in the bone-marrow and hypercalcemia 
did not indicate any significant difference by ethnicity (Figure 12C, Figure 12D).  
When we examined differences in prognostic markers by ethnicity, we observed 
significantly elevated beta-2-microglobulin levels in NHB patients compared to 
Hispanics (Figure 13A). We also observed a lower median M spike in Hispanics than 
NHBs, with no significant difference compared to NHWs (Figure 13B). High beta-2-
microglobulin levels and M spikes signify tumor burden and adverse prognosis in MM 
patients, indicating that Hispanics have a favorable survival indicators than NHB 
patients. We did not find any significant difference in median LDH and albumin levels in 




















Figure 12. Diagnostic Biomarker Levels in Hispanic, NHW and NHB Patients 
The box plots illustrate median levels of diagnostic biomarkers that indicate the CRAB 
symptoms i.e. (A.) serum hemoglobin (B.) serum creatinine (C.) serum calcium and 
(D.) median percentage of plasma cells in the bone marrow, stratified by NHW (purple), 
























 Figure 13. Prognostic Biomarker Levels in Hispanic, NHW and NHB Patients 
The box plots illustrate median levels of prognostic biomarkers to dictate staging of MM 
i.e. (A.) serum B2M (beta-2-microglobulin) (B.) serum M protein spikes (C.) serum 
albumin and (D.) median lactate dehydrogenase (LDH), stratified by NHW (purple), 




Overall Survival by Ethnicity and Genetic Ancestry 
 
 
We report the overall survival and Kaplan-Meier curve of all patients stratified by 
ethnicity; but further divided into the incident and prevalent group of cases for those 
recruited prior and after the year 2010, respectively. As expected, there was a 
confounding effect from MM prevalence in Figure 14 with a higher median survival time 
of 6 - 8 years that do not align with the average median survival time of approximately 5 
- 6 years in the general population(47, 124). After controlling for this survival bias by 
stratifying patients by incident/prevalent cases, the median survival times in Hispanics 
(6.9 years), NHBs (6.6 years), and NHW (6.5 years) did not significantly differ by 
race/ethnicity. Consequently, the Cox regression estimates (with NHWs as reference) 
adjusted for age, gender, and high-risk cytogenetics did not significantly vary by 
race/ethnicity (Figure 15).  
Similarly, the effect size for survival for every 10% increase of each European, 
African, or Amerindian lineage was close to 1.0 (Table 15), suggesting that genetic 
ancestry may not be a factor influencing overall survival in Hispanics or other racial 
populations. Several iterations of genetic ancestry percentages were tested with no 
























Figure 14. Overall Survival of MM Cases by Ethnicity 
 Kaplan Meier curves show overall survival of the entire MM patient cohort  



















Figure 15. Overall Survival of MM Cases by Ethnicity and Diagnosis Year 
Kaplan Meier curves show overall survival of the entire MM patient cohort stratified by 
ethnicity (NHW, Hispanic, NHB) and further stratified by patients diagnosed before and 
after year 2010. Solid lines indicate those diagnosed after 2010, and dashed lines 
correspond to those diagnosed prior to 2010. HR is hazard ratio (95% CI) for patients 
diagnosed after 2010 adjusted for age, gender, and high-risk cytogenetics. NHW is 









Table 15. Overall Survival by Genetic Ancestry 
           Ancestry *HR (95% CI) P-value  
         European (K2) 1.00 (0.97-1.03) 0.69 
         European (K4) 0.99 (0.93-0.86) 0.93 
         European (K1) 1.00 (0.89-1.12) 0.98 
         African (K3) 1.02 (0.99-1.05) 0.36 
         Amerindian (K5) 1.01 (0.94-1.08) 0.74 
HR is the effect size for survival for every 10% increase of a given 





This Chapter demonstrated differences in clinical features such as age of 
diagnosis, Ig subtype, previous diagnosis of MM precursors, and cytogenetic 
abnormalities in Hispanics compared to NHW and NHB cases. Parallel to past findings, 
Hispanics had the youngest average age of diagnosis (57.4 years) followed by NHBs 
(57.5 years) and NHWs (61.2 years).  
Moreover, we discovered that mutations characteristically associated with poor 
prognosis (del 13, del 17p, t(4;14), t(11;14), t(14;16), t(14;20)), occurred at a varying 
rates in our Hispanic, NHW, and NHB patients. The NHB cases had the lowest 
frequency of these mutations, followed by Hispanics and NHW patients. We also found 
that Hispanics with > 40% European ancestry were at increased risk of these mutations 
compared to those with < 40% European genetic ancestry. Studies have shown some 
level of association with high-risk cytogenetic abnormalities and European ancestry, but 
this is the first study that provided a comparative group, Hispanics with a varying 
fraction of European ancestry, to determine if European ancestry is indeed a 
contributing factor of high-risk cytogenetic abnormalities.   
We currently do not have a comparison for MM cytogenetic data in Hispanics. 
However, when investigating the chromosomal changes of acute lymphoblastic 
leukemia (ALL) a B-cell malignancy closely related to MM, the Philadelphia 
chromosome (Ph+), i.e., t(9;22) translocation mutations associated with favorable 
prognosis(125), is found less commonly in Hispanics than NHW patients(126, 127). 
ALL is relatively well studied in Hispanics due to the high incidence rate in Hispanic 
children(126, 128). Unfortunately, research on mutational changes of B-cell 
malignancies, including MM, remains limited in the Hispanic population. Here, we 
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present a meaningful stepping stone for understanding the genetics of MM 
development in subjects of diverse backgrounds and how that affects their outcomes 
for personalized and effective disease management. 
We also reported that the prior reported diagnosis rate of MGUS/SMM was 
lower in Hispanics (8.4%) compared to NHW (18.8%) and NHB (16.1%) patients. 
Literature shows evidence of the differential prevalence of MM premalignancy by 
ancestral background. Our findings somewhat parallel to Landgren’s group results, 
which described a drop in the prevalence rate of MGUS/SMM after the age of 70 in 
Mexican Hispanics when compared to NHW and NHB patients(37).  
Furthermore, one study reported MGUS prevalence to be 2.4% in Mexico 
residents compared to the estimated 3% prevalence rate in Caucasians(129), pointing 
to a potential lower incidence rate of MGUS and SMM in Hispanics. In contrast, another 
of Landgren’s population based study revealed a prevalence rate of MGUS in Mexican 
Americans aged 10-49 to be almost double that those of their white counterparts, but 
lower than blacks in the same aged group(130).  
The lack of routine screening of MM precursors makes it challenging to ascertain 
the "true" rate of MGUS and SMM in Hispanics or other ethnic groups. Nevertheless, 
with additional studies, the rate of MM progression may be better understood for 
improved observations of patients with the pre-cancerous diagnosis. However, we did 
not detect an ancestral association between MGUS/SMM prevalence and genetic 
ancestry in Hispanics.    
Moreover, we identified differences in diagnostic markers like hemoglobin level 
and creatinine levels between Hispanics and NHBs. Compared to Hispanics, NHB 
patients exhibited a significantly lower median hemoglobin level of 10.1 g/dL compared 
to Hispanics (11.4g/dL). Similarly, creatinine levels were slightly elevated in NHB cases 
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compared to Hispanics. Likewise, we found some favorable staging factors in 
Hispanics such as lower levels of median beta-2-microglobulin (P = 0.034) and serum 
M spike (P = 0.020) when compared to NHBs. However, these variations did not 
translate to differences by genetic ancestry (data not shown). Levels of diagnostic and 
prognostic markers did not show significant variation between self-identified Hispanics 
and NHW patients (Figure 12 and Figure 13).  
To our knowledge, the first baseline clinical characteristics in U.S. Hispanic 
patient population were described in 2017 abstract at ASH by Tania et al(49) using 
NHW patients as a comparison group. We take a step further by adding NHB patients 
in our comparative analysis for inclusive reporting. We found the significant differences 
in baseline biomarkers were mainly between Hispanics and NHB patients, with 
Hispanic cases showing favorable levels of diagnostic and prognostic markers. We are 
limited in our sample size, but we confirm the varied clinical characteristics, such as 
slightly elevated hemoglobin levels in Hispanics at diagnosis. In contrast, median M 
spike levels were not significantly different in Hispanics compared to NHW patients but 
were significantly lower than that of NHBs. These clinical feature variations between 
ethnicities warrant continued exploration in larger populations and validation in other 
institutes and public datasets. 
Lastly, after adjusting for MM prevalence, age, gender, and poor prognosis 
cytogenetics, we found no significant differences between overall survival and 
ethnicity/genetic ancestry. Hispanics have been shown to have adverse MM survival 
compared to whites. Evidence attributes this disparity to lagged initiation of therapy(47) 
as well as reduced utilization of ASCT(131) and novel treatments(132) in U.S. 
minorities. Our study may support this attribution as most of our patients received their 
therapy from one specialized institute. In parallel, there is exponential growth of MM 
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experimental treatment advancements, but there is an underrepresentation of  
minorities in clinical trial participation compared to NHW patients(133). Therefore, 
advocating for awareness of treatment disparity by race/ethnicity may reduce the 
poorer survival trends in Hispanics and other minority patients.   
In conclusion, we presented unique disease characteristics in self-reported 
Hispanics and genetic ancestry, which may provide meaningful and timely information 













Chapter 5: Findings Summary, Discussion, and Suggestions for 
Further Research
 94 
Findings Summary and Discussion 
            
            
  
This study identified genetic and clinical contributors of MM susceptibility and 
outcomes and addressed the mediating factors of racial/ethnic disparities of this 
disease in a diverse study population. Our study also addressed gaps in our knowledge 
of MM disease profile in Hispanics.  
Chapter 2 aimed to identify the genetic mediators of MM susceptibility within the 
Wnt/beta-catenin pathway. We found seven variants associated with MM risk in non-
Hispanic whites in the discovery population, of which LRP6:rs7966410 and 
LRP6:rs7956971 remained protective of MM risk in the internal and external 
populations. Rs7966410 and rs7956971 also tagged causal variants with potential 
regulatory effects in known genes associated with MM development, such 
as DKK1 and Myc. 
  Furthermore, by performing cross-ethnic comparisons of candidate variants 
associated with MM risk, we identified two variants, CSNK1D:rs9901910 and 
BTRC:rs7916830, that replicated in the non-Hispanic black and Hispanic patient 
populations. CSNK1D:rs9901910 was found to be a consistent risk locus among non-
Hispanics white (OR: 2.40; 95% CI: 1.67-3.45; P = 2.43 x 10-6), non-Hispanic black 
(OR: 6.42; 95% CI: 2.47-16.7; P = 3.14 x 10-4), and Hispanic (OR: 4.31; 95% CI: 1.83-
10.1; P = 8.10 x 10-4) patients. BTRC:rs7916830 was associated with a 37% and 21% 
reduced risk of MM in the non-Hispanic white and non-Hispanic black populations, 
respectively, indicating differences in MM genetic etiology by race/ethnicity.  
The biological inference of candidate variants through gene regulations are 
described in detail in Chapter 2 using in silico tools. However, additional studies, such 
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as the downstream cellular effects of identified variants in MM cells, is needed to 
evaluate the functional consequences. For instance, transcriptional regulation of 
essential genes modulated by the Wnt/beta-catenin pathway, such as Myc and cyclin 
D1 via candidate causal variants on LRP6, may be good candidates for exploring 
biological mechanism.  
We are limited with the small sample size of Hispanic and NHB subjects to form 
definitive conclusions on our findings' significance. Therefore, additional analysis on a 
larger patient population is needed for validation of our results. However, MM genetic 
association scans are held primarily in European descents, and to our knowledge, 
there are no MM germline genetic studies in Hispanics(134). Our study provides a 
much-needed contribution to genetic research that encapsulates diverse patient 
populations in identifying MM risk loci. 
In Chapter 3, we estimated the proportions of genetic ancestry in our study 
populations. Using these estimations, we found, for the first time, suggestive evidence 
of a 12% protective effect of Amerindian genetic ancestry in MM susceptibility. 
However, this discovery requires external validation on a larger Hispanic study 
population. Moreover, our findings revealed a significant increase of MM risk for every 
10% increase of African ancestry among our NHB study groups, confirming the 
relationship between excessive MM incidence and genetic ancestry in individuals of 
African descent.  
The average age diagnosis in our Hispanic study subjects (57.4 years) 
compared to NHBs (57.5 years) and NHWs (61.0 years), parallel past studies showing 
early disease onset in this subgroup(135-137). Prior cases of MM precursors were also 
the lowest in Hispanics, compared to NHW and NHB patients. Moreover, high-risk 
cytogenetic abnormalities were more common in NHWs and Hispanics than NHBs. 
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Furthermore, Hispanic patients with European ancestry of > 40% had a 3-fold 
increased risk of carrying high-risk cytogenetic abnormalities than those with < 40% of 
European ancestry.   
Our study population did indicate some protective diagnostic and prognostic 
biomarker levels of hemoglobin, creatinine, beta-2-microglobulin, and serum M spikes 
in Hispanics, compared to NHBs; but no significant differences between Hispanics and 
NHW patients. Moreover, we did not find significant differences in prognosis by self-
reported ethnicity or genetic lineage, suggesting that the reported adverse survival in 
Hispanics may not be influenced by biology but instead by treatment access(47). 
When investigating genetic heritage and disease/phenotype risk, it is crucial not 
to lump Hispanic/Latino populations as one admixed group due to their highly diverse 
genetic, continental, and regional backgrounds. The Hispanic/Latino lineage in the 
present-day Americas (including the U.S.), the Caribbean, and Mexico is a varying 
combination of European, African, Amerindian, and some East Asian ancestry 
depending on the history of population mixture between Indigenous Americans 
(Amerindians), Africans brought to the Americas and the Caribbean through the 
transatlantic slave trade, as well as European and East Asian settlers(138, 139).  
Several studies have presented the differential ancestral population structure of 
Hispanics using AIMs from reference populations that harbor genetic loci with varying 
allele frequencies due to geographic isolation(71, 140–142). For instance, Wang et al., 
using reference population from Africa, Europe, and East Asia, found admixed Puerto 
Rican individuals to have a high European ancestral proportion of over 70%, compared 
to Mexicans and Peruvians, that display lower European genetic ancestry of 44% and 
46%, respectively. Also, Mexicans exhibit the influence of East Asian origin (32%) 
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compared to Peruvians (51%), which had Chinese-origin populations initially settled in 
the coastal valleys of Peru(119).  
Similarly, Salzano et al. illustrates the predominantly African influence in the 
Caribbean Latino population, i.e., Jamaicans (78% - 82%), and Haitians (96%). In 
contrast we find more European/Spanish influence in countries like Cuba (73% - 86%) 
and Puerto Rico (60% - 76%) and a higher prevalence of Amerindian ancestry in 
Guatemala (53%) and Mexico (51% - 56%). Mexican lineage also harbors some 
European ancestry (40% - 45%) and a small share of African ancestral influence (2% - 
5%)(119), demonstrating the vast genetic diversity of European, Amerindian, and 
African ancestry within Hispanics and the Latin American microcosm.  
Additionally, there is variability in the Hispanic/Latino lineage by regions in the 
United States. Bryc and colleagues published a paper demonstrating in great detail the 
admixture trends of Hispanics and Europeans that display high variability in ancestral 
percentages based on recent migration patterns within the United States(139). They 
reported the highest percentage of Native American/Amerindian ancestry in self-
reported Latinos from Southwest states, especially those bordering Mexico, mirroring 
the Amerindian legacy in the area and the recent immigration trends through the 
Southwest border. Interestingly, they found a high percentage of African ancestry 
(20%) in self-identified Latinos living in southern states like Louisiana, Georgia, and 
North Carolina, and also states further north like New York and Pennsylvania. The 
study also highlighted the prevalence of European ancestry in self-reported Hispanics 
residing in states like Florida, Kentucky, and Tennessee(139).  
These differences in population structure across the United States is also 
reflected in the concentration of Hispanic or Latino population in different regions of the 
U.S. According to the 2010 U.S. Census Briefs, over half of the Mexican origin 
 98 
population reside in California and Texas alone. Salvadorians make up most of the 
Hispanic/Latino population in Maryland and the District of Colombia(104). Furthermore, 
Hispanics with countries of origin from the Dominican Republic and Puerto Ricans were 
more likely to reside in the Northeast, whereas Cubans were more likely to live in the 
South. "More than three-quarters of the Cuban population (77 percent) resided in the 
South, more than three-quarters of Dominicans (78 percent) resided in the Northeast, 
and more than half of the Puerto Rican population (53 percent) lived in the 
Northeast”(104). This may explain the higher proportion of European ancestry in states 
like Florida through residents of Cuban origins and Northeastern states' African 
influence through concentration of self-reported Puerto-Ricans and Dominicans in the 
region. 
Moreover, there is genetic diversity within the Mexican population alone. The 
Monero-Estrada group at USCF showed divergence in ancestry in indigenous 
Mexicans as well as Mexican-Americans in Los Angeles (MXL), stating, "Some groups 
[indigenous population in Mexico] were as differentiated as Europeans are from East 
Asians"(143). This underscores the nuances of the Hispanic/Latino ancestral diversity 
through geographic origin regions of residence and to take into consideration the vast 
heterogeneity of these groups when studying complex diseases. 
In addition, cancer incidence rates also differ substantially across Latinos by 
residency and national origin. Cuban Latinos and Puerto Ricans residing in the U.S. 
report a higher incidence rate of colorectal and lung cancer than those living in their 
respective countries of origin and also compared to Mexican Americans(109), 
suggesting consideration of environmental factors when investigating the incidence rate 
of MM and other cancers by genetic ancestry. Therefore, it is essential to understand 
the fine-scale population structure and cultural as well as environmental background of 
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the Hispanic/Latino study subjects when conducting epidemiologic or biomedical 
studies. 
Study Limitations and Suggestions for Further Investigation 
 
 
In addition to the small sample size, this study has several limitations. Our 
patient population was collected from a specialized institute, echoed by the above-
average 6.4 - 7 years median survival rates of our subjects. Although there have been 
continuous improvements in survival throughout the years, the median survival time in 
the general population is about five years. Therefore, validation is necessary for other 
multi-ethnic study populations in a larger and non-specialized center for generalizability 
findings.   
As mentioned above, the Hispanic population is a highly diverse group with 
varying genetics by regions. Therefore, the inclusion of Hispanic/Latino residents in 
multiple states of the US and collaborative efforts with hospitals in Latin and Central 
American countries will provide a strong understanding of the genetic and clinical 
mediators of MM development in Hispanics. In addition, it would also be interesting to 
study differences in MM incidence and outcomes in Hispanics/Latinos with varying 
degree of African genetic ancestry.  
Similarly, genome-wide association studies are useful to identify the genetic 
etiology of MM individuals of elevated Amerindian ancestry. Local admixture mapping 
studies have successfully identified multiple independent risk variants on 8q24 and 
found commonly in men of African descent to explain the high incidence rate of 
prostate cancer in black Americans(144, 145). Likewise, conducting local admixture 
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and fine-mapping studies in MM cases of Amerindian heritage may help identify 
chromosomal segments associated with reduced risk of MM in Hispanics. 
Moreover, active and systematic recruitment of diverse group of subjects in MM 
investigative studies through community outreach and clinical trials would be very 
beneficial to narrow the gaps in our understanding of highly heterogenous MM and also 
the racial/ethnic disparities that exist in MM development.  
 
 Final Remarks 
 
In conclusion, we performed the first inclusive, multi-ethnic comparison of MM 
disease characteristics and presented unreported clinical and genetic features of MM in 
Hispanics. Our study is applicable for clinical research addressing the racial/ethnic 
disparity associated with MM and providing a better understanding of disease in the 
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